US20200297608A1 - Compositions containing natural extracts and use thereof for skin and hair - Google Patents
Compositions containing natural extracts and use thereof for skin and hair Download PDFInfo
- Publication number
- US20200297608A1 US20200297608A1 US16/895,990 US202016895990A US2020297608A1 US 20200297608 A1 US20200297608 A1 US 20200297608A1 US 202016895990 A US202016895990 A US 202016895990A US 2020297608 A1 US2020297608 A1 US 2020297608A1
- Authority
- US
- United States
- Prior art keywords
- skin
- hair
- activity
- natural
- catalase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 210000004209 hair Anatomy 0.000 title claims abstract description 75
- 239000000284 extract Substances 0.000 title abstract description 109
- 241000206618 Porphyridium Species 0.000 claims abstract description 29
- 239000002028 Biomass Substances 0.000 claims abstract description 26
- 239000006286 aqueous extract Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 43
- 210000004761 scalp Anatomy 0.000 claims description 37
- 244000134540 Polymnia sonchifolia Species 0.000 claims description 20
- 235000003406 Polymnia sonchifolia Nutrition 0.000 claims description 19
- 238000011282 treatment Methods 0.000 abstract description 32
- 239000002537 cosmetic Substances 0.000 abstract description 13
- 210000003491 skin Anatomy 0.000 description 138
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 113
- 230000000694 effects Effects 0.000 description 94
- 239000000843 powder Substances 0.000 description 54
- 229960002163 hydrogen peroxide Drugs 0.000 description 53
- 210000000282 nail Anatomy 0.000 description 47
- 102000016938 Catalase Human genes 0.000 description 41
- 239000003795 chemical substances by application Substances 0.000 description 40
- 108010053835 Catalase Proteins 0.000 description 28
- 230000032683 aging Effects 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 230000000699 topical effect Effects 0.000 description 26
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 25
- 229960004452 methionine Drugs 0.000 description 25
- 239000000049 pigment Substances 0.000 description 25
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 23
- 229930195722 L-methionine Natural products 0.000 description 23
- 239000003963 antioxidant agent Substances 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 239000000725 suspension Substances 0.000 description 20
- 230000003078 antioxidant effect Effects 0.000 description 19
- 235000006708 antioxidants Nutrition 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 102000006587 Glutathione peroxidase Human genes 0.000 description 17
- 108700016172 Glutathione peroxidases Proteins 0.000 description 17
- 210000002510 keratinocyte Anatomy 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 230000036541 health Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 210000003780 hair follicle Anatomy 0.000 description 15
- 241000195493 Cryptophyta Species 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 108030002440 Catalase peroxidases Proteins 0.000 description 13
- 206010047642 Vitiligo Diseases 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 230000002441 reversible effect Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 239000003642 reactive oxygen metabolite Substances 0.000 description 12
- 206010040882 skin lesion Diseases 0.000 description 12
- 231100000444 skin lesion Toxicity 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 11
- 230000002708 enhancing effect Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 230000000593 degrading effect Effects 0.000 description 10
- 230000008030 elimination Effects 0.000 description 10
- 238000003379 elimination reaction Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- RDIMQHBOTMWMJA-UHFFFAOYSA-N 4-amino-3-hydrazinyl-1h-1,2,4-triazole-5-thione Chemical compound NNC1=NNC(=S)N1N RDIMQHBOTMWMJA-UHFFFAOYSA-N 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 9
- 230000002789 catalaselike Effects 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- -1 propylene glycol Chemical class 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 230000007794 irritation Effects 0.000 description 8
- 239000002738 chelating agent Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000037308 hair color Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000009759 skin aging Effects 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000003712 anti-aging effect Effects 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 230000003648 hair appearance Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000036555 skin type Effects 0.000 description 5
- 238000000527 sonication Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241001494715 Porphyridium purpureum Species 0.000 description 4
- 240000000851 Vaccinium corymbosum Species 0.000 description 4
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940008099 dimethicone Drugs 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000036559 skin health Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 229940042585 tocopherol acetate Drugs 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 238000008998 Catalase assay kit Methods 0.000 description 3
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 3
- 102000010445 Lactoferrin Human genes 0.000 description 3
- 108010063045 Lactoferrin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 241000206572 Rhodophyta Species 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 238000000498 ball milling Methods 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007398 colorimetric assay Methods 0.000 description 3
- 229940086555 cyclomethicone Drugs 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000010902 jet-milling Methods 0.000 description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 3
- 229940078795 lactoferrin Drugs 0.000 description 3
- 235000021242 lactoferrin Nutrition 0.000 description 3
- 235000021374 legumes Nutrition 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- VYGQUTWHTHXGQB-FFHKNEKCSA-N retinyl palmitate Natural products CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 244000257022 tick clover Species 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 240000001548 Camellia japonica Species 0.000 description 2
- 235000006467 Camellia japonica Nutrition 0.000 description 2
- 241000522190 Desmodium Species 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 206010068489 Idiopathic guttate hypomelanosis Diseases 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241001134768 Porphyridium sordidum Species 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000519995 Stachys sylvatica Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229940071160 cocoate Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000003581 cosmetic carrier Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004709 eyebrow Anatomy 0.000 description 2
- 210000000720 eyelash Anatomy 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- CKNYEUXAXWTAPK-UHFFFAOYSA-N 4-octoxy-4-oxobutanoic acid Chemical compound CCCCCCCCOC(=O)CCC(O)=O CKNYEUXAXWTAPK-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 241000649729 Acalyphoideae Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000206615 Bangiophyceae Species 0.000 description 1
- 241001532031 Beaucarnea hookeri Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010009691 Clubbing Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 244000102216 Crateva tapia Species 0.000 description 1
- 235000003495 Crateva tapia Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 240000004585 Dactylis glomerata Species 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 244000090764 Desmodium intortum Species 0.000 description 1
- 244000262912 Desmodium triflorum Species 0.000 description 1
- 241001491743 Dixoniella grisea Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000206652 Florideophyceae Species 0.000 description 1
- 238000009017 Fluorometric Assay Kit Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 240000008892 Helianthus tuberosus Species 0.000 description 1
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000197811 Hieracium fendleri Species 0.000 description 1
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028698 Nail dystrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000009193 PUVA therapy Methods 0.000 description 1
- 244000215747 Pachyrhizus erosus Species 0.000 description 1
- 235000001591 Pachyrhizus erosus Nutrition 0.000 description 1
- 235000018669 Pachyrhizus tuberosus Nutrition 0.000 description 1
- 241000206620 Porphyridiaceae Species 0.000 description 1
- 241001302393 Porphyridium sp. Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 1
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241001262105 Sargassum muticum Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000748489 Smallanthus Species 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000656 anti-yeast Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229940075285 dandruff control Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000020788 dietary exposure Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229940058180 edetate dipotassium anhydrous Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- VEVFSWCSRVJBSM-HOFKKMOUSA-N ethyl 4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 VEVFSWCSRVJBSM-HOFKKMOUSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003646 hair health Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 244000257095 hetero Species 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 108010020410 methionine sulfoxide reductase Proteins 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 230000036562 nail growth Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- PREFCHVVKZWHMM-UHFFFAOYSA-N octan-3-yl 2-hydroxyoctadecanoate Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)OC(CC)CCCCC PREFCHVVKZWHMM-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 210000004918 root sheath Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/10—Preparations for permanently dyeing the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/51—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/594—Mixtures of polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- Hair graying (canities), or the loss of pigment production and deposition within the hair shafts, is an obvious sign of aging, which is highly undesirable in many cultures. Hair graying is a complex phenomenon resulting from the interaction of several intrinsic and extrinsic factors. Intrinsic factors may include genetically programmed processes that could lead to premature graying, genetic diseases, and intrinsic aging processes. Extrinsic factors may include environmental factors (e.g. wind, heat, cigarette smoke, chemicals, UV irradiation, etc.), nutritional effects, medications effects, and emotional stress. All these elements induce molecular and cellular processes that contribute to the loss of hair pigmentation.
- Intrinsic factors may include genetically programmed processes that could lead to premature graying, genetic diseases, and intrinsic aging processes.
- Extrinsic factors may include environmental factors (e.g. wind, heat, cigarette smoke, chemicals, UV irradiation, etc.), nutritional effects, medications effects, and emotional stress. All these elements induce molecular and cellular processes that contribute to the loss of hair pigment
- hair dyeing (“coloring”)
- coloring was documented archeologically from about 1500 BC, and is still popular today.
- hair coloring has several limitations. The borderline of the hair coloring area becomes visible as hairs grow, creating a less aesthetic appearance than desired, and disclosing the undesired aging process. Hair dyeing requires the use of chemicals that are unhealthy or destructive to the hair or the surrounding skin, as well as to the environment, such as hydrogen peroxide. Professional hair dyeing is associated with significant costs and schedule obligations, and home procedures entail a major time commitment, staining and disorder. It is desired, therefore, to have better procedures and methods to solve the hair graying problem.
- a topical treatment that could prevent, slow, reduce or reverse hair graying. It is more desired to have such a treatment as a single and affordable topical treatment for daily skin and hair care. Such a treatment should provide solutions to hair graying with little or no irritation and few or no negative side effects and should further provide other desired scalp and hair health, wellness and beautifying benefits. It is further desired to have a topical treatment that does not require a pharmaceutical prescription.
- Skin aging is a slow, chronic process, in which the functionality of skin molecules and structures is reduced with time and is further compromised with UV exposure. Skin aging is first noticed with the appearance of facial sagging, fine lines, wrinkles and age spots, followed by the appearance of dull and thinning hair, sparse eyebrows and eyelashes, and dry and fragile skin and nails.
- the anti-aging market provides remedies and solutions directed mainly to enhance facial beauty. It is desired to have “anti-aging” products that affect the molecular and cellular processes contributing to the aging process, and provide additional functional benefits, not just cosmetic effects.
- Oxidative stress (or the imbalance between reactive oxygen species (ROS) creation and the ability to detoxify ROS and repair the resulting damage) is increased with age and with UV exposure, while the antioxidant response of the aging cells slows with the accumulation of mutations. ROS induce inflammatory processes and immune-suppression, which further contribute to barrier damage and compromise skin integrity. Clinical data suggest that reducing oxidative stress contributes to skin health and wellness and reduces aging manifestations. It is desired to have an “anti-aging” skin care solution that not only reduces oxidative stress, but also enhances the endogenous antioxidant response of the aging cells.
- IGH idiopathic guttate hypomelanosis
- Vitiligo is a disorder in which white, non-pigmented patches of skin appear on different parts of the body.
- the vitiligo lesions are large patches, they expand rapidly, and they are not related to sun exposure or aging.
- Vitiligo may arise from autoimmune, genetic, neural, or viral causes, as well as from oxidative stress. In some cases, vitiligo spreads slowly, over many years, however, in other cases the spreading occurs very quickly. Some reports associate the increase in white patches with physical or emotional stress.
- the most commonly prescribed treatment for vitiligo is a potent or super-potent topical corticosteroid. Unfortunately, only about 45 percent of patients regain some skin color following months of this treatment. Light therapy is very ineffective, and PUVA therapy does not provide satisfactory results as well.
- a topical treatment that could preserve the natural skin color, or prevent, or slow, or reduce or reverse pigment loss in vitiligo. It is more desired to have such a treatment as a single and affordable topical treatment for daily skin care. Such a treatment should provide solutions to vitiligo with little or no irritation and few or no negative side effects, and should further provide other desired skin health, wellness and beautifying benefits.
- Geriatric skin (generally referred to the skin of individuals 65 years old or older, but the age can vary due to numerous factors) is significantly aged and therefore very fragile. It is thin and dry, very itchy, easily bruised and predisposed to wounding, tearing and infections, therefore affecting both health and quality of life. In the elderly skin, the aging processes continue and magnify. The amount of inflammatory infiltrate is increased, wound healing and immune responses are delayed, thermoregulation is compromised and sweat and sebum production are decreased. The cumulative effects of life-long environmental exposure further enhance functional skin aging in the elderly. These include not only UV exposure, pollution and smoke, but also factors like air conditioning, heating and hot water use.
- geriatric skin The major needs of geriatric skin are not related to facial beauty, but to the health and well-being of body skin. What is needed is to reduce dryness and itchiness, to reduce the amount and the severity of skin injuries, to reduce skin tears, reduce hematomas, enhance the healing time of minor injuries, reduce the rate of infections, and the like. Unfortunately, there are few, if any, consumer products dedicated to these geriatric skin needs. Geriatric skin could benefit from enhancing its biological properties and reducing undesired attributes such as pruritis or fragility in a way superior to the use of moisturization alone. It is desired to have a topical treatment that could prevent, slow, reduce or reverse skin aging processes in geriatric skin.
- Such a treatment should provide solutions to geriatric skin needs, with little or no irritation and few or no negative side effects to the fragile skin, and should further provide other desired health, wellness and cosmetic benefits. It is further desired to have such a single topical treatment that does not require a pharmaceutical prescription.
- compositions for the topical delivery of a natural extract(s) product comprising a natural product(s) such as, but not limiting to, a botanical extract, an algae extract, a yeast extract, a fungi extract or a microorganism extract, or a fraction(s) of such extract, or a combination(s) thereof (collectively defined as “natural extract”).
- a natural extract(s) product e.g., to a mammal in need thereof, such as a human
- a natural product(s) such as, but not limiting to, a botanical extract, an algae extract, a yeast extract, a fungi extract or a microorganism extract, or a fraction(s) of such extract, or a combination(s) thereof (collectively defined as “natural extract”).
- the natural extracts of this disclosure (1) contain active, non-denatured catalase and/or glutathione peroxidase, or (2) have a catalase-like activity (e.g.
- catalase-enhancing activity e.g. enhancing gene expression, protein translation or other activity that leads to an increase in hydrogen peroxide degradation or elimination
- catalase stabilizing activity e.g. enhancing gene expression, protein translation or other activity that leads to an increase in hydrogen peroxide degradation or elimination
- catalase-related activity e.g. enhancing gene expression, protein translation or other activity that leads to an increase in hydrogen peroxide degradation or elimination
- catalase stabilizing activity e.g. enhancing gene expression, protein translation or other activity that leads to an increase in hydrogen peroxide degradation or elimination
- catalase stabilizing activity e.g. enhancing gene expression, protein translation or other activity that leads to an increase in hydrogen peroxide degradation or elimination
- catalase stabilizing activity e.g. enhancing gene expression, protein translation or other activity that leads to an increase in hydrogen peroxide degradation or elimination
- catalase stabilizing activity e.g. enhancing gene expression, protein translation or other activity that leads to an increase in hydrogen peroxide degradation or elimination
- compositions of this disclosure further comprise of delivery system(s), or vehicle(s), or stabilizing system(s) that enable to maintain an active catalase-related activity, and deliver such an activity into the skin, the nail or the hair follicles.
- compositions described in this disclosure could be used for skin, hair and nail care, to provide skin, scalp, hair and nail with health and wellness benefits, and to provide skin, scalp, hair and nail with anti-aging and with geriatric skin benefits.
- compositions described in this disclosure could be used to reduce the visibility of the signs of skin, scalp, hair and nail aging and the signs of geriatric skin.
- the present disclosure also features a method of reducing the hair graying process of a mammal, said method comprising the step of applying a composition described herein to the scalp or to other desired skin areas with hair or to non-glabrous skin.
- Gray hair is defined as the hair that has changed its color from the original natural hair color due to biological processes such as aging, chemical exposure, environmental exposure, nutritional exposure, medicine exposure and the like, and is of reduced color, or achromatic color, or an intermediate between white and black that is lighter than the original natural hair color.
- Human non-glabrous skin is defined as all human skin areas that are hairy, or that can grow hair or that can contain hair follicles.
- Non-glabrous skin refers to all external skin that is not naturally hairless, and excludes only the skin found on the ventral portion of the fingers, palms, soles of feet, lips, labia minora, and glans penis.
- Reducing hair graying includes, but is not limited to the preservation of the natural color of the hair, or to reducing the quantity or quality of loss of the natural hair color or to the slowing, reducing, or reversing the process of hair graying, or to preventing hair graying, or to reducing the visibility of hair graying.
- compositions described in this disclosure could also be used to preserve the natural color of the skin, or to slow, or to reduce, or to delay, or to reverse the loss of pigment on the skin or the uneven decay in the natural color of the skin, or to reduce the visibility of hypo-pigmentary skin lesions (including, but not limiting to, pigment-loss lesions, “white spots”, IGH and vitiligo lesions).
- Such lesions include, but are not limited to, age-induced white, or lighter than the natural skin color, or hypo-pigmented spots (e.g. idiopathic guttate hypomelanosis, IGH), and disease-induced pigmentary loss (e.g. vitiligo).
- the present disclosure also describes a method of reducing the appearance of non-pigmented skin areas of a mammal, said method comprising the step of applying the above compositions to the desired skin areas.
- the present disclosure relates to methods of preserving the natural color of the hair, or slowing the decay in the natural pigment production of the hair follicle, or delaying, or slowing, or reducing the severity of hair graying, or reducing the appearance of hair graying, by applying a composition containing a safe and effective amount of a natural extract.
- the natural extract could be supplemented with, enriched with or combined with L-methionine.
- the present disclosure relates to methods of preventing the decay in the natural pigment production of the hair follicle and reducing the appearance of hair graying, by applying a composition containing a safe and effective amount of a natural extract.
- the natural extract could be supplemented with, enriched with or combined with L-methionine.
- the present disclosure relates to methods of partially or completely reversing the decay in the natural pigment production of the hair follicle and reducing the appearance of hair graying, by applying a composition containing a safe and effective amount of a natural extract.
- the natural extract could be supplemented with, enriched with or combined with L-methionine.
- the present disclosure features a product including a composition comprising a natural extract and instructions directing the user to apply the composition to the hair, scalp, or other skin areas with hair (non-glabrous skin), in order to preserve the natural hair color, or slow, or prevent or reverse the decay in the natural pigment production of the hair follicle, or slow, or prevent or reverse the appearance of hair graying.
- hairy skin areas include, but are not limited to the scalp, head, eyebrows, eyelashes, beard, mustache, chest, back, arms, legs and the like.
- the present disclosure features a method of promoting a product including a composition containing a natural extract by directing the user to apply said composition to the hair, scalp or hairy skin areas, or non-glabrous skin, in order to preserve the natural hair color, or to slow, or prevent or reverse the decay in the natural pigment production of the hair follicle, or to slow, or prevent or reverse the appearance of hair graying.
- the present disclosure relates to methods of preserving the natural color of the skin, or of slowing the uneven decay in the natural pigment production of the aging skin, or of delaying, or slowing, or reducing the severity or the visibility of loss-of-pigment lesions (e.g. IGH, “white spots”, or vitiligo), by applying a composition containing a safe and effective amount of a natural extract.
- the present disclosure relates to methods of preserving the natural color of the skin, or of slowing the development of pigmentary skin loss, or of delaying, or slowing, or reducing the severity of mottled pigment loss, by applying a composition containing a safe and effective amount of a natural extract.
- the natural extract could be supplemented with, enriched with or combined with L-methionine.
- the present disclosure relates to methods of preserving the natural color of the skin, or of preventing the decay in the uneven pigment production of the skin, or of reducing the appearance of non-pigmented skin lesions, by applying a composition containing a safe and effective amount of a natural extract.
- the natural extract could be supplemented with, enriched with or combined with L-methionine.
- the present disclosure relates to methods of partially or completely reversing the uneven decay in the pigment production of the skin, or reducing the appearance of non-pigmented skin lesions, by applying a composition containing a safe and effective amount of a natural extract.
- the natural extract could be supplemented with, enriched with or combined with L-methionine.
- the present disclosure features a product including a composition comprising a natural extract and instructions directing the user to apply the composition to the affected or desired skin areas, in order to preserve the natural skin color, or to slow, or prevent, or reverse the decay in the production of pigment in the skin, or to slow, or prevent or reverse the appearance of non-pigmented skin lesions.
- the present disclosure features a method of promoting a product including a composition containing a natural extract by directing the user to apply said composition to the affected or desired skin areas, in order to preserve the natural color of the skin, or to slow, or prevent or reverse the decay in the pigment production of the skin, or to slow, or prevent or reverse the appearance of non-pigmented skin lesions.
- the present disclosure relates to methods of enhancing skin, scalp, hair and nail health and wellness, beautifying the skin, hair and nail, providing anti-aging benefits, or enhancing the biological properties and the health and wellness of elderly skin, by applying a composition containing a safe and effective amount of a natural extract to the skin (both glabrous and non-glabrous areas) to enhance skin health, wellness and appearance.
- a composition containing a safe and effective amount of a natural extract to the skin (both glabrous and non-glabrous areas) to enhance skin health, wellness and appearance.
- the natural extract could be supplemented with, enriched with or combined with L-methionine.
- the anti-aging benefits of the compositions of this disclosure would include the desired structural, functional and visual effects on wrinkles, sagging, “age spots”, and other signs and symptoms of facial skin aging.
- the geriatric skin benefits of the compositions of this disclosure would include enhancing the structural and functional properties of elderly nails, facial-, scalp- and body-skin, reducing dryness of facial, scalp and body skin, reducing skin pruritis, reducing skin and nail fragility, reducing the quantity and severity of hematomas, reducing the quantity and the severity of skin tears and other skin wounds, reducing skin infections, and enhancing wound healing of skin wounds.
- Body skin is referred to all human skin areas, including nails, and in particular to the skin of the arms, hands, fingers, legs and feet.
- the present disclosure features a product including a composition comprising a natural extract and instructions directing the user to apply the composition to the affected or desired skin, scalp and nail areas, in order to enhance skin, scalp and nail health and wellness, to reduce the signs of skin aging, or to combat the reduced qualities and problems of geriatric skin.
- the present disclosure features a method of promoting a product including a composition containing a natural extract by directing the user to apply said composition to the affected or desired skin, scalp and nail areas, in order to enhance skin, scalp and nail health and wellness, to reduce the signs of skin, scalp, hair and nail aging, or to combat the reduced qualities and problems of geriatric skin.
- the present disclosure relates to the recognition that certain natural extracts are very effective in the elimination of hydrogen peroxide, and therefore they could be used for preserving the natural color of skin and hair, or for preventing, or slowing, or reducing or reversing the appearance of hair graying or depigmented skin lesions, or for reducing the general signs of skin, scalp, hair and nail aging and the specific signs of geriatric elderly skin.
- Amor Seco Desmodium Adscendens, Desmodium coeruleum, D. caespitosum, D. glaucescens, D. heterophyllum, D. oxalidifolium, D. triflorum, Hedysarum adscendens, H. caespitosum, Meibomia adscendens
- Amor Seco is a tree species of the Acalyphoideae, native to South America. It is locally known as tamanqueiro, tapia or amor seco. It grows preferentially in riparian forests, reaching a height of 10-20 m.
- Amor Seco leave powder is produced from Amor Seco leaves, which are cleared of foreign material and are milled and grinded. The powder is used as a food additive (see e.g. http://www.nutricargo.com/herb-powders/amor-seco-powder).
- Amor Seco leave powder has hydrogen peroxide degrading activity (see Example 1). Moreover, exposure of human keratinocytes to Amor Seco leave powder results in an enhancement of the endogenous cellular activity of the keratinocytes in degrading or eliminating hydrogen peroxide (see Example 2). Additionally, Amor Seco leave powder exhibited strong activity against hydrogen-peroxide-induced oxidative stress (example 3). These results suggest that Amor Seco leave powder could be used topically, on skin, scalp, nail and hair, to reduce hydrogen peroxide concentration, and therefore to be useful in this disclosure. The topical use of Amor Seco leave powder should slow, delay and reduce the progression of hair graying.
- the topical use of Amor Seco leave powder should reduce the visibility of depigmented skin lesions and could reduce the signs of skin, scalp, hair, and nail aging and enhance elderly skin properties. It is expected that other plants of the family Fabaceae, and not only those from the genus Desmodium, would have similar biological properties and could also be used in a similar manner.
- Yacón Smallanthus sonchifolius, Syn.: Polymnia edulis, P. sonchifolia, Peruvian ground apple
- Yacón is a perennial plant traditionally grown in the Northern and Central Andes from Colombia to Northern Argentina for its crisp, sweet-tasting tuberous roots. Commonly called “jicama” in Ecuador, yacón is sometimes confused with this unrelated plant. Yacón is actually a close relative of the sunflower and Jerusalem artichoke.
- Yacón leave powder has hydrogen peroxide degrading or eliminating activity (see Example 1). Moreover, exposure of human keratinocytes to Yacón leave powder results in an enhancement of the endogenous cellular activity of the keratinocytes in degrading or eliminating hydrogen peroxide (see Example 2). Additionally, Yacón leave powder exhibited strong activity against hydrogen-peroxide-induced oxidative stress (Example 3). These results suggest that Yacón leave powder could be used topically, on skin, scalp, nail and hair, to reduce hydrogen peroxide concentration and provide beneficial effects. The topical use of Yacón leave powder should slow, delay or reduce the progression of hair graying.
- the topical use of Yacón leave powder should reduce the visibility of depigmented skin lesions, and could reduce the signs of skin, scalp, hair, and nail aging and enhance elderly skin properties. It is expected that other plants of the family Asteraceae, and not only those from the genus Smallanthus, would have similar biological properties and could also be used in a similar manner.
- the red microalgae Porphyridium (Genus: Porphyridium, including, but not limiting to Phytoconis purpurea Bory de Saint-Vincent, 1797, Porphyridium Nageli, Byssus purpurea Lamarck, Olivia cruenta S.F.Gray, Arlington cruenta S.F.Gray, Porphyridium cruentum (S.F.Gray) Nägeli, Porphyridium marinum Kylin, Sarcoderma sanguineum Ehrenberg, P ⁇ rphyridium sp. UTEX 637 or a strain derived from Porphyridium sp.
- the algae biomass (the algae cells) is removed while the secreted polysaccharide is retained.
- the precipitated algae biomass is sometimes considered a waste product, which is discarded during the production of the polysaccharide.
- the algae is rich in xanthine derivatives, which are sometimes extracted from the biomass for nutritional uses. In other times the algae pigments are extracted from the biomass.
- dried Porphyridium biomass has hydrogen peroxide degrading and eliminating activity (see Example 1). Moreover, exposure of human keratinocytes to dried Porphyridium biomass results in an enhancement of the endogenous cellular activity of the keratinocytes in degrading and eliminating hydrogen peroxide (see Example 2). These results suggest that dried Porphyridium biomass could be used topically, on skin, scalp, nail and hair, to reduce hydrogen peroxide concentration and provide beneficial effects.
- the topical use of dried Porphyridium biomass should slow, delay and reduce the progression of hair graying. Similarly, the topical use of dried Porphyridium biomass should reduce the visibility of depigmented skin lesions, and could reduce the signs of skin, scalp, hair, and nail aging and enhance elderly skin properties.
- Red microalgae suitable for this disclosure include the unicellular algae of the Bangiophyceae, Florideophyceae, Goniotrichales, Dixoniella grisea, or other member of the Rhodophyta.
- compositions and methods of this disclosure will vary with the area being treated, the age, health and skin and hair type of the end user, the duration and nature of the treatment, the specific composition employed, the particular condition being treated, the particular cosmetically- or pharmaceutically-acceptable carrier utilized, and like factors.
- the present disclosure describes a natural extract(s) or their fraction(s), or combination(s) thereof (1) containing active, non-denatured catalase, or (2) having a catalase-like activity, or (3) having a catalase-enhancing activity, or (4) having a catalase-stabilizing activity, or mixtures thereof.
- the natural extract described in this disclosure can be, but is not limited to, a plant extract, an algae extract, a yeast extract, a fungi extract, a microorganism extract, or a fraction(s) of such extract(s), or combinations thereof.
- the natural extracts of this disclosure are aqueous.
- Aqueous extracts are materials that were extracted by any solvent consisting totally or partially of water, including, but not limited to water itself, aqueous/alcoholic solvents in any proportion, or solvents comprising water and a compound such as propylene glycol, in any proportion.
- the aqueous extract could be in a liquid form or could be dried out to a solid form.
- an enhancement of catalase production within the natural source is achieved by (1) selecting relevant genetic variants, or (2) using genetic engineering technologies, or (3) controlling a timed and selective exposure (e.g. continuous, pulsed, at a defined growth phase) to hydrogen peroxide, or (4) controlling a timed and selective exposure to different wavelengths (e.g. UV, blue, or others), or (5) providing certain ingredients (e.g. chemicals, nutritional agents) that affect the growth or the biological properties of the natural source, before collecting the natural source for extraction, or combinations thereof.
- a timed and selective exposure e.g. continuous, pulsed, at a defined growth phase
- different wavelengths e.g. UV, blue, or others
- certain ingredients e.g. chemicals, nutritional agents
- the natural source (1) could be grown under nutritional conditions that enrich for L-methionine, or (2) could be grown under nutritional conditions that enhance the production of L-methionine, or (3) could be supplemented with L-methionine during growth, or (4) could be engineered to produce or retain L-methionine, or (5) could be combined with L-methionine during the preparation and processing of the natural extract.
- the L-methionine enriched extract could be used in all the compositions and methods disclosed herein, and is expected to have superior effects in reducing hydrogen peroxide concentrations in skin, scalp, hair and nail.
- the fertilization of plants is performed with a micronutrient composition that includes high levels of L-methionine.
- Another example relates to the enrichment of the growth medium of algae, fungi, yeast and other microorganisms with about 0.1-100 mM L-methionine, which can lead to increased methionine in the extracts prepared from these materials.
- the natural extract e.g. Amor Seco leave powder, Yacón leave powder or dried Porphyridium biomass, or their aqueous extracts
- the effective concentration of L-methionine in the composition should be about the same as the concentration of hydrogen peroxide within the affected tissue (e.g. the graying hair follicle, the vitiligo lesion, the elderly skin, and the like). This concentration varies with the age, gender, skin type and hair type of the individual, and with their specific need (e.g. hypo-pigmented lesions, gray hair, elderly skin, and the like). Lower concentrations (high micromolar range) would be effective for geriatric skin, while higher concentrations (low milimolar range) would be required for affecting gray hair and hypo-pigmentary skin lesions.
- the natural extracts of this disclosure are non-denatured, and contain stable and active proteins like the catalase enzyme or the glutathione peroxidase enzyme.
- “Denaturation” is defined in the Bantam Medical Dictionary (1990 edition) as “the change in the physical and the physiological properties of a protein, that are brought about by heat, X-rays or chemicals. These changes include loss of activity in the case of enzymes”.
- “non-denatured product” is a natural product in which the processing for the derivation of such product (e.g., the temperature, extraction media) did not eliminate its specific hydrogen peroxide elimination activity.
- extracts of this disclosure could be further purified, or concentrated or fractionated or combined to increase the content of the catalase enzyme or the glutathione peroxidase enzyme or the catalase-like activity.
- the natural sources of this disclosure would consist of unused or “wasted” natural products.
- examples for such sources include, but are not limited, to leaves and stems that are not collected in the field, or are collected and then separated, when fruits, vegetables, roots and grains are harvested, and might be otherwise discarded or provided for animal feed.
- Other examples include plants parts that are removed during food processing, like legume pods or fruit and vegetable peels.
- Another example includes botanical parts that are removed during the processing or production of specific botanical products, such as the algae biomass that is removed during the production of the algae polysaccharide.
- Extracts of this disclosure can be tested for their hydrogen peroxide eliminating activity using colorimetric or spectrophotometric assays such as the Catalase Assay Kit of Cayman Chemical (#707002), the BioVision Inc. Catalase Activity Colorimetric/Fluorometric Assay Kit (#K773-100), The Sigma Aldrich Enzymatic Assay of Catalase (EC 1.11.1.6) kit, the AmplexAE Red Catalase Assay Kit (#A22180) of Molecular Probes, or the like.
- Such assays are sensitive to detect pico units of catalase activity within samples.
- the catalase enzyme itself can also be detected and quantified within the extracts using standard procedures, however the existence of the protein does not guarantee its activity, and therefore the activity assays are preferred, and are used to define the natural extracts.
- the natural extracts of this disclosure contain catalase-like activity, namely the ability to degrade or eliminate hydrogen peroxide, directly or indirectly, without containing an intact catalase or glutathione peroxidase enzyme.
- such extracts could be further concentrated, or purified, or fractionated, or combined to increase the content of the catalase-like activity.
- such extracts could be tested for their hydrogen peroxide eliminating activity using similar assays to those describe above, as such assays are measuring the reaction products and not the enzyme concentrations. Such extracts could be defined, therefore, by their hydrogen peroxide eliminating activity.
- Topically applied agents of relatively large molecular weight have the potential to reach pharmacologically active concentrations at the hair bulb, if properly formulated with adequate delivery vehicles.
- the delivery occurs via the junction of the internal and external root sheath, and the higher molecular weight molecules are confined to the follicular structures immediately surrounding the hair shaft.
- the natural extracts containing catalase-like activity of this disclosure could be size fractionated and selected, and then concentrated, or combined, to increase the concentration of smaller molecular weight ingredients with the desired activity within the composition.
- the molecular weight of the ingredients having the desired activity is smaller than that of catalase.
- the molecular weight of the ingredients having the desired activity is smaller than 1 kDa. The size of ⁇ 0.5 kDa is considered the largest for passive skin penetration (Bos J D, Meinardi M M H M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000 9:165-16)].
- the molecular weight of the ingredients having the desired activity is smaller than ⁇ 0.5 kDa.
- the natural extract of this disclosure could enhance the gene expression, or the protein translation, or the stability, or the activity of the endogenous catalase enzyme or the endogenous glutathione peroxidase enzyme in the skin, or the nail, or the hair follicle.
- such extracts could be further concentrated, or purified or fractionated or combined to enhance such an activity.
- such extracts could be defined by their hydrogen peroxide eliminating activity.
- extracts of this disclosure that enhance the expression, or the stability, or the activity of the endogenous skin, scalp, nail, or hair follicle catalase enzyme and/or glutathione peroxidase enzyme could be size fractionated and selected, and then concentrated, or combined, to increase the concentration of smaller molecular weight ingredients with the desired activity in the composition.
- the molecular weight of the ingredients that enhance the expression, or the stability, or the activity of the endogenous skin, nail, scalp or hair follicle catalase and/or glutathione peroxidase enzyme is smaller than that of catalase.
- the molecular weight of the ingredients that enhance the expression, or the stability, or the activity of the endogenous skin or hair follicle catalase and/or glutathione peroxidase enzyme is smaller than 1 kDa. In yet another aspect, the molecular weight of the ingredients that enhance the expression, or the stability, or the activity of the endogenous skin or hair follicle catalase and/or glutathione peroxidase enzyme is smaller than 0.5 kDa.
- the natural extracts of this disclosure can be evaluated for their catalase and/or glutathione peroxidase enhancing activity in skin, scalp, hair or nail or in their relevant in vitro systems.
- in vitro systems include, but are not limited to epidermal, or dermal, or epidermal-dermal skin constructs that can be obtained commercially, e.g. from MatTek corporation, monolayers of melanocytes, epidermal keratinocytes, dermal fibroblasts or follicular keratinocytes that can be obtained commercially, e.g. from ATTC, skin explants with and without hair that can be obtained from e.g. human and animal biopsies, cultured hair plugs, and the like.
- an example of such an assay includes the incubation of the biological samples with and without the extracts of this disclosure, using a range of safe and effective concentrations, for different time points (e.g. 24, 48 and 96 hours).
- the biological samples can be homogenized and tested for hydrogen peroxide elimination activity using the assays described above, or they can be tested for irritation biomarkers, sensitization biomarkers, inflammatory responses, anti-oxidant responses and the like using known procedures. Additionally, they can be tested for the enhanced expression or stability of the endogenous catalase and/or glutathione peroxidase enzyme, or of other cellular anti-oxidant enzymes, using standard molecular procedures. Additionally, the biological samples can be challenged (e.g.
- catalase and/or glutathione peroxidase expression and activity can be evaluated using known and validated assays for e.g. catalase and/or glutathione peroxidase expression or activity, irritation, sensitization, inflammatory responses, anti-oxidant responses and the like. Viability can be evaluated with e.g. a standard MTT assay. Irritation and inflammatory responses can be evaluated e.g. by measuring the release of inflammatory cytokines such as IL-1 alpha into the culture media, using standard ELISA techniques. Anti-oxidant responses can be measured with standard assays e.g. using ABTS (trolox equivalent) or DPPH kits. Catalase and/or glutathione peroxidase expression and stability can be evaluated using standard techniques such as QPCR or protein immune-reactivity over time.
- the novel compositions of this disclosure contain aqueous natural extracts, which might be present in many forms such as of a fluid or a solid.
- the aqueous natural product is in the form of a suspension.
- One way to make the natural suspension is to soak the fresh or dry natural sources in a liquid (e.g. water) for from about 10 minutes to several hours, and after they were fully hydrated to press, or grind them, to allow the ingredients to be extracted. Procedures such as pressure disruption, sonication and milling (e.g., jet milling and ball milling, sometimes performed under cold or freezing conditions) can be used instead of grinding, to break down the biological material for improved extraction.
- the suspension may be filtered to remove any residual parts. In one example the suspension is filtered using a 0.2 micron pore size filter.
- the natural suspension could be dried by e.g. tray drying, spin drying, rotary drying, spin flash drying, or lyophilization.
- the natural suspensions and solutions used in this disclosure can use fresh natural sources, or may be made from dry, powdered natural sources and liquid.
- the powder is milled (e.g. by pressure disruption, sonication, jet milling or ball milling and the like) from the natural sources (e.g. botanical parts, algae, fungi or microorganism cultures and the like) and may also be dried (e.g.
- the resulting powder may or may not be filtered.
- the suspension or solution is filtered using a 0.2 micron pore size filter.
- Such prepared suspension or solutions may have from about 0.01 to about 90% by weight dry powder.
- Another example is the use of natural extract powder, made from, e.g. lyophilized, spray dried or freeze-dried suspension as described above and the like, with the addition of liquid and with or without filtration or homogenization.
- the active ingredients could be extracted from ground natural sources using ethanol/water mixtures, followed by the removal of the ethanol from the extract, in such ways that the specific catalase and/or glutathione peroxidase activity or catalase-related activity of the preparation will be retained.
- Known methods of fractionation could be used to separate and concentrate the desired activities of this disclosure, or to size fractionate the natural extract, or to eliminate inhibitory or undesired activities.
- the natural extracts of this disclosure could be produced using electro-kinetic potential (Zeta) fractionation and separation (e.g.
- Zeta FractionTM Technology http://www.sc.akzonobel.com/en/personalcare/Pages/zeta-fraction.aspx)
- Zeta Fraction technology can selectively isolates intracellular components from biological sources, e.g. from plants “juices”, without the use of external solvents for separation.
- Targeted fractions with active catalase and/or glutathione peroxidase, or with catalase-like activity could be mechanically separated based on their electro-kinetic (zeta) potential, to be used in compositions of this disclosure.
- the zeta fractions could be further processed (e.g. filtered, dried, combined) as described above.
- the fresh or dry natural source of this disclosure could be grinded or milled as described above, suspended in a liquid (e.g. water) and then undergo a mechanical homogenization, or a particle-size reduction (e.g. by sonication, or shear mixing, or homogenization, or any other known semi solid processing, sometimes performed under cold or freezing conditions) to create a homogenate (so that the cells or biomass of the natural source are broken or disrupted).
- the resulting suspension could then be separated (e.g. by centrifugation of e.g. 500-1,000 RPM for 10 minutes, or by similar procedures), and the supernatant could be further size-selected (e.g.
- compositions of this disclosure “as is”, or could be dried-out using standard procedures (e.g. lyophilized, spin-dried, spray dried, tray dried, spin flash dried, freeze-dried and the like) to create a more refined natural extract. All such processes should not create unreasonable heat that might reduce or eliminate the biological activity of the natural extract.
- Useful compositions can include stabilization systems, which may include one or more preservatives, or one or more anti-oxidants, or one or more chelating agents, or combinations thereof.
- Preservatives are useful for substantially preventing microbial decomposition. Examples of preservatives include, but are not limited to phenoxyethanol, parabens and natural preservatives, and are known to the ones skilled in the art. Other examples of preservatives could be found on pages 1654-55 of the International Cosmetic Ingredient Dictionary and Handbook, eds.
- the composition may comprise from about 0.01% to about 20%, by weight (sometimes more preferably, from about 0.5% to about 5%, by weight) of preservative.
- Microbial contamination can also be eliminated by gamma irradiation, or electron-beam irradiation, or X-ray irradiation and the like, by microfiltration, or by other standard procedures (e.g. brief heat treatments) that do not result in the elimination of the specific activity described in this disclosure.
- Antioxidants and/or chelating agents may also be used to increase shelf life and stability of the compositions. Antioxidants may be added both for formulation stabilization and for biological efficacy.
- Antioxidant compounds and their derivatives include, but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cystein), lipoic acid and dihydrolipoic acid, resveratrol, acetyl-cysteine (Iniferine®) or lactoferrin, and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbyl polypeptide).
- water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cystein), lipoic acid and dihydrolipoic acid, resveratrol, acetyl-cy
- Oil-soluble antioxidants suitable for use in the compositions of this disclosure include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol acetate), tocotrienols, and ubiquinone.
- Natural extracts containing antioxidants suitable for use in the compositions of this disclosure include, but are not limited to, extracts containing flavonoids and isoflavonoids and their derivatives (e.g., genistein and diadzein), extracts containing resveratrol, extracts containing polyphenols and the like.
- compositions of the present disclosure may comprises the antioxidant in an amount of from about 0.001% to about 20%, by weight (e.g., from about 0.01% to about 10% by weight) of the composition.
- Chelating agents are also useful in assisting the stabilization of compositions.
- chelating agents include, but are not limited to EDTA and derivatives thereof (e.g., disodium EDTA and dipotassium EDTA), Iniferine lactoferrin, and citric acid.
- Other examples of chelating agents are listed on page 1626 of the Cosmetic Handbook.
- the compositions of the present disclosure may comprise the chelating agent in an amount of from about 0.001% to about 20%, by weight (e.g., from about 0.01% to about 10% by weight) of the composition.
- Thickening agents may be used to alter the viscosity of useful compositions.
- the desired viscosity of the composition will depend upon the intended use (e.g., as a shampoo, conditioner, mousse, cream, lotion, ointment, serum, spray, gel, stick, or the like).
- the viscosity of the composition should be relatively low, similar to an aqueous solution.
- Application as a cream, lotion, or gel will have slightly higher viscosity (e.g., between about 100 cps and 100,000 cps).
- Thickening agents that can be added to the compositions of this disclosure to alter viscosity include polymers such as sepigels or polyacrylates (e.g., polyacrylamide, other carbomers) or polysaccharides (e.g. chitosan). Other examples of viscosity modifying agents are listed on pages 1692-97 of the Cosmetic Handbook. To achieve the appropriate viscosity, compositions of the present disclosure may comprise from about 0.01% to about 20%, by weight (e.g., from about 0.1% to about 5%, by weight) of a thickening agent.
- compositions containing natural extracts can also contain other cosmetically active agents (e.g., a synthetic compound(s) or a compound(s) isolated from a natural source, or a natural extract(s) containing a mixture of compounds that has a cosmetic or therapeutic effect on the tissue).
- cosmetically active agents e.g., a synthetic compound(s) or a compound(s) isolated from a natural source, or a natural extract(s) containing a mixture of compounds that has a cosmetic or therapeutic effect on the tissue.
- the useful compositions described herein may also contain other skin-, hair- and nail-beneficial agents in addition to the natural product(s). Examples of such agents include, but are not limited to, anti-inflammatory agents (such as corticosteroids, NSAIDs, or botanical extracts with anti-inflammatory activity such as Aloe Vera), anti-pruritic agents, topical analgesics, antioxidants (e.g.
- agents with catalase-like or SOD-like activity e.g. salem MN compounds such as the family of EUK agents
- epidermal-, dermal- and follicular-regenerating agents and agents that enhance skin, hair and nail tissue regeneration agents including e.g. retinoids, retinoid-derivatives, retinol, retinal, alpha hydroxy acids, co-enzyme-Q, growth factors, and others
- antibiotics and anti-microbial agents, anti-mycotic agents, anti-yeast agents, anti-parasites, agents that enhance the immune system, dandruff-control and shine-control agents including e.g.
- miconazole miconazole, ketoconazole, elubiol, itraconazole, coal tar and the like agents
- detergents surfactants, moisturizers, nutrients, vitamins, minerals, energy enhancers, hair or nail growth enhancing agents, agents that delay hair growth, agents for skin conditioning, odor-control agents (such as e.g. odor masking or pH-changing agents), deodorants, antiperspirants, colorants, pigments, color-masking agents, agents that enhance pigment production or pigment delivery (e.g.
- agents that enhance or inhibit pigment production agents that affect methionine sulfoxide reductase activity (e.g. L-methionine, that could prevent the oxidation of methionine) and other agents that enhance skin, scalp, hair or nail wellness and beauty that are known to those of ordinary skill in the art.
- agents that affect methionine sulfoxide reductase activity e.g. L-methionine, that could prevent the oxidation of methionine
- other agents that enhance skin, scalp, hair or nail wellness and beauty that are known to those of ordinary skill in the art.
- compositions described herein may also contain compounds that enhance the feel of the composition on the skin, scalp, hair or nail of the user.
- examples of such compounds include, but are not limited to, oils, silicones (e.g., siloxane polymers such as dimethicone), polymers, polysaccharides, and skin-conditioning agents such as emollients, and humectants. Some examples of such skin conditioning agents may be found of pages 1656-1670 of the Cosmetic Handbook.
- the compositions useful herein can contain conventional cosmetic adjuvants, such as colorants (such as dyes and pigments), opacifiers (e.g., titanium dioxide), and fragrances, which are known to those skilled in the art in the field of this disclosure.
- the composition and formulations containing such compositions of the present disclosure may be prepared using methodology that is well known by an artisan of ordinary skill.
- compositions of this disclosure may be used, but are not limited to, with cosmetically or pharmaceutically accepted forms and carriers such as solutions, suspensions, emulsions (including microemulsions and nanoemulsions), lotions, creams, gels, sticks, sprays, ointments, cleansing liquids, washes, solid bars, shampoos, hair conditioners, nail polishes, nail strengtheners, pastes, foams, powders, mousses, shaving creams, shaving gels, wipes, patches, hydrogels, film-forming products, masks, liquid drops, muco-adhesives, and the like.
- cosmetically or pharmaceutically accepted forms and carriers such as solutions, suspensions, emulsions (including microemulsions and nanoemulsions), lotions, creams, gels, sticks, sprays, ointments, cleansing liquids, washes, solid bars, shampoos, hair conditioners, nail polishes, nail strengtheners, pastes, foams, powders, mousses, shaving creams, shaving gels
- compositions of this disclosure may be packaged in a tube, a sealed packet, a jar, a pump, a bottle, a can, a pledget, a towelet, a dispenser, a wipe, a spray can or the like.
- An airtight or a light-blocking package e.g. such as an aluminum tube, aluminum pocket, pump, or laminated tube, can also be used to further enhance product stability.
- compositions of this disclosure further comprise of delivery systems that enable to maintain an active catalase and/or glutathione peroxidase enzyme or catalase-related activity, and deliver the active ingredients, possibly including active proteins, into the hair follicles, or into the nail, or into the skin.
- delivery systems may include micro- and nano-particles, liposomes, aspasomes, organogels, niosomes, transferosomes, patches, micro- and nano-needles, micro- and nano-capsules, micro- and nano-sponges, films, polymers, and the like.
- the present disclosure features a method of reducing the hair graying process of a mammal, said method comprising the step of applying to the scalp or to other desired non-glabrous skin areas a safe and effective amount of the compositions of this disclosure.
- the frequency of the application will vary with the area being treated, the age, health, hair type and skin type of the end user, the duration and nature of the treatment, the specific composition employed, the particular cosmetically- or pharmaceutically-acceptable carrier utilized, and like factors. For example, in some instances the application would be periodic, while in other instances the application would be once or twice daily.
- the present disclosure features a method of reducing non-pigmented lesions on the skin of a mammal (e.g. of an age-induced or UV-induced pigment loss spots, or IGH, or vitiligo), said method comprising the step of applying to the skin areas a safe and effective amount of the compositions of this disclosure.
- the frequency of the application will vary with the area being treated, the age, health and skin type of the end user, the duration and nature of the treatment, the specific composition employed, the particular cosmetically- or pharmaceutically-acceptable carrier utilized, and like factors. For example, in some instances the application would be periodic, while in other instances the application would be once or twice daily.
- the present disclosure also features a method of reducing the signs and symptoms of skin, scalp, hair and nail aging and enhancing the biological properties and the health and wellbeing of geriatric skin, said method comprising the step of applying to the skin, scalp, hair or nail areas in need a safe and effective amount of the compositions of this disclosure.
- the frequency of the application will vary with the area being treated, the age, health and skin type of the end user, the duration and nature of the treatment, the specific composition employed, the particular cosmetically- or pharmaceutically-acceptable carrier utilized, and like factors. For example, in some instances the application would be periodic, while in other instances the application would be once or twice daily.
- safe and effective amount means an amount of the composition sufficient to induce a desired effect on hair, nail or skin, but low enough to avoid serious side effects.
- the safe and effective amount of the composition will vary with the area being treated, the age, health, hair type and skin type of the end user, the duration and nature of the treatment, the specific composition employed, the particular cosmetically- or pharmaceutically-acceptable carrier utilized, and like factors.
- a Catalase assay kit was obtained from Cayman Chemical Co. (Ann Arbor, Mich.). The assay measures hydrogen peroxide elimination activity (e.g. catalase activity) using Purpald (4-amino-3-hydrazino-5-mercapto-1,2,4-triazole) as chromogen in a colorimetric assay. The testing involves the changes in optical density (OD) at 540 nm, which is proportional to the effective activity present in the sample based on the reaction with methanol in the presence of hydrogen peroxide. Purpald, used as chromogen, forms a bicyclic heterocycle with the formaldehyde produced, which upon oxidation changes from colorless to purple color.
- OD optical density
- Sample powders of the naturals were suspended in water or PBS at 5% (w/v), sonicated to break the material to sub-micron particles, homogenized, and centrifuged at 1,000 RPM for 10 min to remove insoluble material.
- Serial dilutions were prepared for each test material and mixed with methanol and hydrogen peroxide in assay buffer solution. Reaction was set for 20 minutes at room temperature. All samples were compared to assay buffer-treated samples (used as negative control).
- Catalase enzyme standard derived from bovine liver, was used as positive control.
- Optical density changes at 540 nm were evaluated after addition of potassium hydroxide, Purpald and potassium periodate.
- Sample powders of the natural test agents were suspended in phosphate buffer (1 ⁇ PBS) at 5% w/v, and were homogenized by sonication. Following a 1,000 RPM spin for 10 minutes, the supernatants were sterilized by filtration using a 0.2 ⁇ m syringe filter, as described in Example 1. The samples (sonicated filtered supernatants of the 5% suspensions) were then serially diluted to the desired test concentrations.
- Primary normal human epidermal keratinocytes NHEKs
- NHEKs Primary normal human epidermal keratinocytes
- cells were treated with or without test materials, at 0.005, 0.05 and 0.5% (concentrations refer to the original 5% suspensions) in culture media, once daily, for 3 days.
- Cells were harvested on the 4 th day and then lysed and total protein concentrations in the lysates were measured using the BSA-Bradford assay.
- Cell lysates were mixed with methanol and hydrogen peroxide in assay buffer. Reaction was set for 20 minutes at room temperature. All samples were compared to assay buffer-treated cells (used as negative control).
- Catalase enzyme standard derived from bovine liver, was used as positive control.
- Optical density changes at 540 nm were evaluated after addition of potassium hydroxide, Purpald and potassium periodate. For the assay, average absorbance was calculated and subtracted from the negative control for each sample and standards.
- a Camellia japonica extract with a strong antioxidant activity was reported to enhanced catalase activity of HaCaT keratinocytes by about 50% only, and an ethanolic fraction of Sargassum muticum extract, at 10%, enriched for anti-oxidant activity, enhanced HaCaT cells catalase activity by 25% only [Antioxidant Effects of the Ethanol Extract from Flower of Camellia japonica via Scavenging of Reactive Oxygen Species and Induction of Antioxidant Enzymes.
- test agents/total protein Test Material Yacon leave Amor Seco leave Dried Porphyridium (%, w/v) powder powder biomass 0.005 1.5 ⁇ 0.1 2.0 ⁇ 0.3 2.7 ⁇ 0.1 0.05 1.8 ⁇ 0.1 2.1 ⁇ 0.4 3.0 ⁇ 0.1 0.5 2.6 ⁇ 0.1 2.5 ⁇ 0.2 3.2 ⁇ 0.1
- the activity (U) is defined as nmol/min/mL. The activity is normalized to the total protein amount in each cell lysate sample, which is defined as U/mg.
- the topical use of Yacon leave powder, or Amor Seco leave powder, or dried Porphyridium biomass should reduce the progression and the visibility of depigmented skin lesions, the signs of skin, scalp, hair, and nail aging, and the problems associated with geriatric skin.
- the purpose of this study was to evaluate intracellular antioxidant activity of test materials in cultured human epidermal keratinocytes, in response to a hydrogen peroxide insult.
- Cells were treated with test materials, labeled with H2DCFDA and later exposed to hydrogen peroxide.
- Relative fluorescence was measured as indicator for intracellular reactive oxygen species (ROS).
- ROS reactive oxygen species
- Test agents were stored at room temperature until use. Sample powders were suspended in phosphate buffer (1 ⁇ PBS) to make 10 mg/mL (1% w/v) stock solutions, vortexed for 1 minute, sonicated on ice for 10 minutes at 30-50% output, centrifuged at 1000 rpm for 10 minutes at 4° C., and the supernatants were sterilized using 0.2 ⁇ m-syringe filter. Such homogenized solutions were prepared for each test material.
- NHEKs Primary normal human epidermal keratinocytes
- the topical use of either Yacon leave powder, or Amor Seco leave powder or dried Porphyridium biomass powder should slow, delay and reduce the progression of hair graying, which is initiated and enhanced by high endogenous hydrogen peroxide levels.
- the topical use of Yacon leave powder, or Amor Seco leave powder, or dried Porphyridium biomass should reduce the progression and the visibility of depigmented skin lesions, the signs of skin, scalp, hair, and nail aging, and the problems associated with geriatric skin.
- the topical treatment with the natural agents of this disclosure would deliver the hydrogen peroxide eliminating activity of the agents themselves, and would additionally enhance the endogenous hydrogen peroxide breakdown or elimination activity of the keratinocytes.
- the effectiveness of these agents is expected at concentrations of from about 0.001% (w/v of powdered natural) and higher.
- Natural extracts can be prepared as liquid samples (suspensions) or as sample powders of the natural source that are suspended in water or phosphate buffer or other aqueous solutions, to make e.g. 10-100 mg/mL (1-10% w/v) stock suspensions.
- the suspensions should be mixed (e.g. vortexed) for e.g. 1-10 minute, and the natural material should then be size-reduced, e.g. at 4° C., to break down the cells (e.g. by pressure disruption, jet milling, ball milling, or sonication e.g. for 10 minutes at e.g. 30-50% output). Larger particles should then be separated (e.g.
- the supernatants can be directly used in the formulation, or could undergo a further size selection (e.g. the suspension or solution can be filtered using a 0.2 micron pore size filter).
- the resulting homogenized solutions of the naturals could be directly used in the formulations, or could be further dried (e.g. lyophilized, spray dried or freeze-dried), and used in the formulation as dry powders.
- gel compositions suitable for this invention are suggested in Tables 4.
- a preservative e.g. Phenonip®, phenoxyethanol
- a chelating agent e.g. Disodium EDTA
- a humectant e.g. glycerin
- the natural extract which is in a liquid form or a powder suspended in liquid, e.g. water.
- oil-soluble silicones, emollients, viscosity builders or emulsifiers e.g.
- cyclomethicone dimethicone, PolySorbate 20, Aluminum Starch Octyl Succinate, Sucrose Cocoate, PEG-6 Capric/Caprylic Triglycerides.
- a thickener(s) e.g. Sepigel®, PolyAquol 2W
- an anti-oxidant e.g. BHT
- BHT anti-oxidant
- Other anti-oxidants e.g. ascorbic acid, sodium ascorbyl phosphate, lactoferrin, or tocopherol
- the natural extracts can be prepared as in example 4. Two examples of oil-in-water emulsions are presented in Table 5.
- the ingredients of the lipid phase should be combined and mixed at about 50-85° C., and then cooled to about 40-60° C.
- the thickener can be slowly combined with the aqueous natural extract or the powder natural extract reconstituted in water or an aqueous solution. After mixing for e.g. about ten minutes the rest of the aqueous phase ingredients can be added and mixed, and then heated to about the lowest possible temperature of the lipid phase.
- the two phases can then be combined, mixed for e.g. for about ten minutes, and cooled to room temperature. Additional active agents may be combined into both phases or after their mixing.
- the biological activity described in this disclosure should be monitored, as excessive heat could reduce the desired activity.
- the natural extracts can be prepared as in example 4.
- Two examples of water-in-oil formulations are presented in Table 6.
- the emollients e.g. mineral oil
- the other oil phase ingredients can then be added and the mixture can be heated e.g. to about 75° C. to enable homogeneous mixing.
- the aqueous phase ingredients can be mixed separately and should be warmed to the lowest possible temperature of the liquid oil phase (while confirming the retaining of biological activity of the natural extract), and then the two mixture can be stirred until it congealed. Additional active agents may be combined into both phases or after their mixing.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present disclosure relates to compositions containing a natural extract(s) and their fraction(s) and the use of such compositions for treatment of skin, hair and nail. For example, the present disclosure relates to compositions containing an aqueous extract of (i) Yacón leave, (ii) Amor Seco leave, or (iii) Porphyridium biomass, or a combination thereof and a pharmaceutically or cosmetically acceptable carrier use on hair skin and nails for cosmetic purposes.
Description
- This application claims priority to U.S. application Ser. No. 15/342,947, filed Nov. 3, 2016, which claims priority to U.S. application Ser. No. 62/256,803, filed Nov. 18, 2015, the entire contents of which is hereby incorporated by reference.
- Hair graying (canities), or the loss of pigment production and deposition within the hair shafts, is an obvious sign of aging, which is highly undesirable in many cultures. Hair graying is a complex phenomenon resulting from the interaction of several intrinsic and extrinsic factors. Intrinsic factors may include genetically programmed processes that could lead to premature graying, genetic diseases, and intrinsic aging processes. Extrinsic factors may include environmental factors (e.g. wind, heat, cigarette smoke, chemicals, UV irradiation, etc.), nutritional effects, medications effects, and emotional stress. All these elements induce molecular and cellular processes that contribute to the loss of hair pigmentation.
- The major approach to address hair graying is hair dyeing (“coloring”), which was documented archeologically from about 1500 BC, and is still popular today. However, hair coloring has several limitations. The borderline of the hair coloring area becomes visible as hairs grow, creating a less aesthetic appearance than desired, and disclosing the undesired aging process. Hair dyeing requires the use of chemicals that are unhealthy or destructive to the hair or the surrounding skin, as well as to the environment, such as hydrogen peroxide. Professional hair dyeing is associated with significant costs and schedule obligations, and home procedures entail a major time commitment, staining and disorder. It is desired, therefore, to have better procedures and methods to solve the hair graying problem.
- It is desired to have a topical treatment that could prevent, slow, reduce or reverse hair graying. It is more desired to have such a treatment as a single and affordable topical treatment for daily skin and hair care. Such a treatment should provide solutions to hair graying with little or no irritation and few or no negative side effects and should further provide other desired scalp and hair health, wellness and beautifying benefits. It is further desired to have a topical treatment that does not require a pharmaceutical prescription.
- Skin aging is a slow, chronic process, in which the functionality of skin molecules and structures is reduced with time and is further compromised with UV exposure. Skin aging is first noticed with the appearance of facial sagging, fine lines, wrinkles and age spots, followed by the appearance of dull and thinning hair, sparse eyebrows and eyelashes, and dry and fragile skin and nails. The anti-aging market provides remedies and solutions directed mainly to enhance facial beauty. It is desired to have “anti-aging” products that affect the molecular and cellular processes contributing to the aging process, and provide additional functional benefits, not just cosmetic effects.
- The mid-50s “free radical theory of aging” correlates cumulative oxidative damage with the degree of aging. Oxidative stress, (or the imbalance between reactive oxygen species (ROS) creation and the ability to detoxify ROS and repair the resulting damage) is increased with age and with UV exposure, while the antioxidant response of the aging cells slows with the accumulation of mutations. ROS induce inflammatory processes and immune-suppression, which further contribute to barrier damage and compromise skin integrity. Clinical data suggest that reducing oxidative stress contributes to skin health and wellness and reduces aging manifestations. It is desired to have an “anti-aging” skin care solution that not only reduces oxidative stress, but also enhances the endogenous antioxidant response of the aging cells.
- One of the more noticeable and unwanted signs of aging is skin pigmentary lesions. The brown spots that appear on UV-exposed skin areas (“age spots”) are one such pigmentary problem. Additionally, age-induced white, hypo-pigmented spots (idiopathic guttate hypomelanosis, IGH) also appear on sun-exposed, aged skin areas, and signal the undesired “old” look. These affected areas may stop making melanin at all, causing them to completely lose pigment, resulting in unsightly, but benign lesions. IGH lesions are commonly found in more than 50% of older and elderly individuals (aged ≥40 years), and about 30% of the individuals develop their initial IGH lesions prior to 20 years of age.
- There is no treatment available for the spotted loss of skin pigmentation such as in IGH. It is desired to have a topical treatment that could preserve the natural skin color, or prevent, or slow, or reduce or reverse spotty skin pigment loss in the pigment-losing areas of the skin such as in IGH. It is more desired to have such a treatment as a single and affordable topical treatment for daily skin care. Such a treatment should provide solutions to spotty skin pigment loss with minimal or no irritation and few or no negative side effects, and should further provide other desired skin health, wellness and beautifying benefits.
- IGH should not be confused with vitiligo, which is a skin depigmenting disease. Vitiligo is a disorder in which white, non-pigmented patches of skin appear on different parts of the body. The vitiligo lesions are large patches, they expand rapidly, and they are not related to sun exposure or aging. Vitiligo may arise from autoimmune, genetic, neural, or viral causes, as well as from oxidative stress. In some cases, vitiligo spreads slowly, over many years, however, in other cases the spreading occurs very quickly. Some reports associate the increase in white patches with physical or emotional stress. The most commonly prescribed treatment for vitiligo is a potent or super-potent topical corticosteroid. Unfortunately, only about 45 percent of patients regain some skin color following months of this treatment. Light therapy is very ineffective, and PUVA therapy does not provide satisfactory results as well.
- It is desired to have a topical treatment that could preserve the natural skin color, or prevent, or slow, or reduce or reverse pigment loss in vitiligo. It is more desired to have such a treatment as a single and affordable topical treatment for daily skin care. Such a treatment should provide solutions to vitiligo with little or no irritation and few or no negative side effects, and should further provide other desired skin health, wellness and beautifying benefits.
- Geriatric skin (generally referred to the skin of individuals 65 years old or older, but the age can vary due to numerous factors) is significantly aged and therefore very fragile. It is thin and dry, very itchy, easily bruised and predisposed to wounding, tearing and infections, therefore affecting both health and quality of life. In the elderly skin, the aging processes continue and magnify. The amount of inflammatory infiltrate is increased, wound healing and immune responses are delayed, thermoregulation is compromised and sweat and sebum production are decreased. The cumulative effects of life-long environmental exposure further enhance functional skin aging in the elderly. These include not only UV exposure, pollution and smoke, but also factors like air conditioning, heating and hot water use. Diseases, and in particular diabetes, immune disorders, cardiac diseases, renal or hepatic failure, malignancies and infections enhance the skin aging process as does the prolonged use of medications like steroids, anticoagulants, blood thinners, immune-modulators and cancer therapies. Slowness and life style changes further contribute to dehydration and reduced skin nutrition, enhancing the dryness and fragility of the elderly skin, and contributing to an increase in “little injuries” and their consequences. Interestingly, it was suggested that most of the elderly skin changes associated with aging are due to intrinsic aging rather than photodamage or lifestyle.
- The major needs of geriatric skin are not related to facial beauty, but to the health and well-being of body skin. What is needed is to reduce dryness and itchiness, to reduce the amount and the severity of skin injuries, to reduce skin tears, reduce hematomas, enhance the healing time of minor injuries, reduce the rate of infections, and the like. Unfortunately, there are few, if any, consumer products dedicated to these geriatric skin needs. Geriatric skin could benefit from enhancing its biological properties and reducing undesired attributes such as pruritis or fragility in a way superior to the use of moisturization alone. It is desired to have a topical treatment that could prevent, slow, reduce or reverse skin aging processes in geriatric skin. It is more desired to have such a treatment as a single and affordable topical treatment for daily care. Such a treatment should provide solutions to geriatric skin needs, with little or no irritation and few or no negative side effects to the fragile skin, and should further provide other desired health, wellness and cosmetic benefits. It is further desired to have such a single topical treatment that does not require a pharmaceutical prescription.
- Elderly patients experience common nail changes and dystrophies that induce pain, affect daily activities, and are of cosmetic concern. With age, nails may become brittle and prone to breaking, may become clubbed (a significant shape-change with very rounded nails), or may be discolored. Unfortunately, there are no consumer products dedicated to elderly nail care, or to the general health and wellbeing of the nails. It is desired to have products to enhance the biological properties of the nails and their surrounding skin and cuticle, and to reduce undesired properties associated with nail aging. It is more desired to have such a product as a single and affordable topical treatment for daily care. Such a treatment should provide solutions to geriatric skin needs, with little or no irritation and few or no negative side effects to the fragile skin, and should further provide other desired health, wellness and cosmetic benefits. It is further desired to have such a single topical treatment that does not require a pharmaceutical prescription.
- The present disclosure features compositions for the topical delivery of a natural extract(s) product (e.g., to a mammal in need thereof, such as a human) comprising a natural product(s) such as, but not limiting to, a botanical extract, an algae extract, a yeast extract, a fungi extract or a microorganism extract, or a fraction(s) of such extract, or a combination(s) thereof (collectively defined as “natural extract”). In one instance, the natural extracts of this disclosure (1) contain active, non-denatured catalase and/or glutathione peroxidase, or (2) have a catalase-like activity (e.g. degrading or eliminating hydrogen peroxide), or (3) have a catalase-enhancing activity (e.g. enhancing gene expression, protein translation or other activity that leads to an increase in hydrogen peroxide degradation or elimination), or (4) have a catalase stabilizing activity, or a combination of one or more such activities (collectively defined as “catalase-related activity” or “catalase-like activity”). In another embodiment, the natural source of this disclosure (e.g. botanical, plant, algae, yeast, fungi or microorganism) could be grown with, or enriched with, or supplemented with, or engineered for producing, or combined with the L-methionine, or the natural extracts themselves could be combined with L-methionine.
- In one embodiment the present disclosure describes a natural extract and a pharmaceutical or a cosmetic carrier. In yet another illustration, the compositions of this disclosure further comprise of delivery system(s), or vehicle(s), or stabilizing system(s) that enable to maintain an active catalase-related activity, and deliver such an activity into the skin, the nail or the hair follicles.
- The compositions described in this disclosure could be used for skin, hair and nail care, to provide skin, scalp, hair and nail with health and wellness benefits, and to provide skin, scalp, hair and nail with anti-aging and with geriatric skin benefits. In yet another feature, the compositions described in this disclosure could be used to reduce the visibility of the signs of skin, scalp, hair and nail aging and the signs of geriatric skin.
- The present disclosure also features a method of reducing the hair graying process of a mammal, said method comprising the step of applying a composition described herein to the scalp or to other desired skin areas with hair or to non-glabrous skin. Gray hair is defined as the hair that has changed its color from the original natural hair color due to biological processes such as aging, chemical exposure, environmental exposure, nutritional exposure, medicine exposure and the like, and is of reduced color, or achromatic color, or an intermediate between white and black that is lighter than the original natural hair color. Human non-glabrous skin is defined as all human skin areas that are hairy, or that can grow hair or that can contain hair follicles. Non-glabrous skin refers to all external skin that is not naturally hairless, and excludes only the skin found on the ventral portion of the fingers, palms, soles of feet, lips, labia minora, and glans penis. Reducing hair graying includes, but is not limited to the preservation of the natural color of the hair, or to reducing the quantity or quality of loss of the natural hair color or to the slowing, reducing, or reversing the process of hair graying, or to preventing hair graying, or to reducing the visibility of hair graying.
- The compositions described in this disclosure could also be used to preserve the natural color of the skin, or to slow, or to reduce, or to delay, or to reverse the loss of pigment on the skin or the uneven decay in the natural color of the skin, or to reduce the visibility of hypo-pigmentary skin lesions (including, but not limiting to, pigment-loss lesions, “white spots”, IGH and vitiligo lesions). Such lesions include, but are not limited to, age-induced white, or lighter than the natural skin color, or hypo-pigmented spots (e.g. idiopathic guttate hypomelanosis, IGH), and disease-induced pigmentary loss (e.g. vitiligo). The present disclosure also describes a method of reducing the appearance of non-pigmented skin areas of a mammal, said method comprising the step of applying the above compositions to the desired skin areas.
- In one aspect, the present disclosure relates to methods of preserving the natural color of the hair, or slowing the decay in the natural pigment production of the hair follicle, or delaying, or slowing, or reducing the severity of hair graying, or reducing the appearance of hair graying, by applying a composition containing a safe and effective amount of a natural extract. In another aspect, the natural extract could be supplemented with, enriched with or combined with L-methionine.
- In another aspect, the present disclosure relates to methods of preventing the decay in the natural pigment production of the hair follicle and reducing the appearance of hair graying, by applying a composition containing a safe and effective amount of a natural extract. In one aspect the natural extract could be supplemented with, enriched with or combined with L-methionine.
- Yet in another aspect, the present disclosure relates to methods of partially or completely reversing the decay in the natural pigment production of the hair follicle and reducing the appearance of hair graying, by applying a composition containing a safe and effective amount of a natural extract. In one aspect the natural extract could be supplemented with, enriched with or combined with L-methionine.
- In another aspect, the present disclosure features a product including a composition comprising a natural extract and instructions directing the user to apply the composition to the hair, scalp, or other skin areas with hair (non-glabrous skin), in order to preserve the natural hair color, or slow, or prevent or reverse the decay in the natural pigment production of the hair follicle, or slow, or prevent or reverse the appearance of hair graying. Such hairy skin areas include, but are not limited to the scalp, head, eyebrows, eyelashes, beard, mustache, chest, back, arms, legs and the like.
- Yet in another aspect, the present disclosure features a method of promoting a product including a composition containing a natural extract by directing the user to apply said composition to the hair, scalp or hairy skin areas, or non-glabrous skin, in order to preserve the natural hair color, or to slow, or prevent or reverse the decay in the natural pigment production of the hair follicle, or to slow, or prevent or reverse the appearance of hair graying.
- In another aspect, the present disclosure relates to methods of preserving the natural color of the skin, or of slowing the uneven decay in the natural pigment production of the aging skin, or of delaying, or slowing, or reducing the severity or the visibility of loss-of-pigment lesions (e.g. IGH, “white spots”, or vitiligo), by applying a composition containing a safe and effective amount of a natural extract. In another aspect the present disclosure relates to methods of preserving the natural color of the skin, or of slowing the development of pigmentary skin loss, or of delaying, or slowing, or reducing the severity of mottled pigment loss, by applying a composition containing a safe and effective amount of a natural extract. In yet another aspect, the natural extract could be supplemented with, enriched with or combined with L-methionine.
- In another aspect, the present disclosure relates to methods of preserving the natural color of the skin, or of preventing the decay in the uneven pigment production of the skin, or of reducing the appearance of non-pigmented skin lesions, by applying a composition containing a safe and effective amount of a natural extract. In yet another aspect, the natural extract could be supplemented with, enriched with or combined with L-methionine.
- Yet in another aspect, the present disclosure relates to methods of partially or completely reversing the uneven decay in the pigment production of the skin, or reducing the appearance of non-pigmented skin lesions, by applying a composition containing a safe and effective amount of a natural extract. In yet another aspect, the natural extract could be supplemented with, enriched with or combined with L-methionine.
- In another aspect, the present disclosure features a product including a composition comprising a natural extract and instructions directing the user to apply the composition to the affected or desired skin areas, in order to preserve the natural skin color, or to slow, or prevent, or reverse the decay in the production of pigment in the skin, or to slow, or prevent or reverse the appearance of non-pigmented skin lesions.
- Yet in another aspect, the present disclosure features a method of promoting a product including a composition containing a natural extract by directing the user to apply said composition to the affected or desired skin areas, in order to preserve the natural color of the skin, or to slow, or prevent or reverse the decay in the pigment production of the skin, or to slow, or prevent or reverse the appearance of non-pigmented skin lesions.
- In yet another instance, the present disclosure relates to methods of enhancing skin, scalp, hair and nail health and wellness, beautifying the skin, hair and nail, providing anti-aging benefits, or enhancing the biological properties and the health and wellness of elderly skin, by applying a composition containing a safe and effective amount of a natural extract to the skin (both glabrous and non-glabrous areas) to enhance skin health, wellness and appearance. In yet another aspect, the natural extract could be supplemented with, enriched with or combined with L-methionine. In yet another aspect, the anti-aging benefits of the compositions of this disclosure would include the desired structural, functional and visual effects on wrinkles, sagging, “age spots”, and other signs and symptoms of facial skin aging. Yet in another aspect, the geriatric skin benefits of the compositions of this disclosure would include enhancing the structural and functional properties of elderly nails, facial-, scalp- and body-skin, reducing dryness of facial, scalp and body skin, reducing skin pruritis, reducing skin and nail fragility, reducing the quantity and severity of hematomas, reducing the quantity and the severity of skin tears and other skin wounds, reducing skin infections, and enhancing wound healing of skin wounds. Body skin is referred to all human skin areas, including nails, and in particular to the skin of the arms, hands, fingers, legs and feet.
- In another aspect, the present disclosure features a product including a composition comprising a natural extract and instructions directing the user to apply the composition to the affected or desired skin, scalp and nail areas, in order to enhance skin, scalp and nail health and wellness, to reduce the signs of skin aging, or to combat the reduced qualities and problems of geriatric skin.
- Yet in another aspect, the present disclosure features a method of promoting a product including a composition containing a natural extract by directing the user to apply said composition to the affected or desired skin, scalp and nail areas, in order to enhance skin, scalp and nail health and wellness, to reduce the signs of skin, scalp, hair and nail aging, or to combat the reduced qualities and problems of geriatric skin.
- Other features and advantages of the present disclosure will be apparent from the detailed description of the disclosure and from the claims. It is believed that one skilled in the art can, based upon the description herein, utilize the present disclosure to its fullest extent. The following specific examples are to be construed as merely illustrative and not limitative of the remainder of the disclosure in any way whatsoever. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure belongs. Also, all publications, patent applications, patents, and other references mentioned herein, are incorporated herein by reference. Unless otherwise indicated, a percentage refers to a percentage by weight (e.g. % (w/v)).
- The present disclosure relates to the recognition that certain natural extracts are very effective in the elimination of hydrogen peroxide, and therefore they could be used for preserving the natural color of skin and hair, or for preventing, or slowing, or reducing or reversing the appearance of hair graying or depigmented skin lesions, or for reducing the general signs of skin, scalp, hair and nail aging and the specific signs of geriatric elderly skin.
- Amor Seco (Desmodium Adscendens, Desmodium coeruleum, D. caespitosum, D. glaucescens, D. heterophyllum, D. oxalidifolium, D. triflorum, Hedysarum adscendens, H. caespitosum, Meibomia adscendens) is a tree species of the Acalyphoideae, native to South America. It is locally known as tamanqueiro, tapia or amor seco. It grows preferentially in riparian forests, reaching a height of 10-20 m. It is essentially an evergreen, though in the hot summer months there is a more pronounced changeover of leaves, and branches are denuded to some extent. Amor Seco leave powder is produced from Amor Seco leaves, which are cleared of foreign material and are milled and grinded. The powder is used as a food additive (see e.g. http://www.nutricargo.com/herb-powders/amor-seco-powder).
- It was unexpectedly found that Amor Seco leave powder has hydrogen peroxide degrading activity (see Example 1). Moreover, exposure of human keratinocytes to Amor Seco leave powder results in an enhancement of the endogenous cellular activity of the keratinocytes in degrading or eliminating hydrogen peroxide (see Example 2). Additionally, Amor Seco leave powder exhibited strong activity against hydrogen-peroxide-induced oxidative stress (example 3). These results suggest that Amor Seco leave powder could be used topically, on skin, scalp, nail and hair, to reduce hydrogen peroxide concentration, and therefore to be useful in this disclosure. The topical use of Amor Seco leave powder should slow, delay and reduce the progression of hair graying. Similarly, the topical use of Amor Seco leave powder should reduce the visibility of depigmented skin lesions and could reduce the signs of skin, scalp, hair, and nail aging and enhance elderly skin properties. It is expected that other plants of the family Fabaceae, and not only those from the genus Desmodium, would have similar biological properties and could also be used in a similar manner.
- Yacón (Smallanthus sonchifolius, Syn.: Polymnia edulis, P. sonchifolia, Peruvian ground apple) is a perennial plant traditionally grown in the Northern and Central Andes from Colombia to Northern Argentina for its crisp, sweet-tasting tuberous roots. Commonly called “jicama” in Ecuador, yacón is sometimes confused with this unrelated plant. Yacón is actually a close relative of the sunflower and Jerusalem artichoke.
- It was unexpectedly found that Yacón leave powder has hydrogen peroxide degrading or eliminating activity (see Example 1). Moreover, exposure of human keratinocytes to Yacón leave powder results in an enhancement of the endogenous cellular activity of the keratinocytes in degrading or eliminating hydrogen peroxide (see Example 2). Additionally, Yacón leave powder exhibited strong activity against hydrogen-peroxide-induced oxidative stress (Example 3). These results suggest that Yacón leave powder could be used topically, on skin, scalp, nail and hair, to reduce hydrogen peroxide concentration and provide beneficial effects. The topical use of Yacón leave powder should slow, delay or reduce the progression of hair graying. Similarly, the topical use of Yacón leave powder should reduce the visibility of depigmented skin lesions, and could reduce the signs of skin, scalp, hair, and nail aging and enhance elderly skin properties. It is expected that other plants of the family Asteraceae, and not only those from the genus Smallanthus, would have similar biological properties and could also be used in a similar manner.
- The red microalgae Porphyridium (Genus: Porphyridium, including, but not limiting to Phytoconis purpurea Bory de Saint-Vincent, 1797, Porphyridium Nageli, Byssus purpurea Lamarck, Olivia cruenta S.F.Gray, Olivia cruenta S.F.Gray, Porphyridium cruentum (S.F.Gray) Nägeli, Porphyridium marinum Kylin, Sarcoderma sanguineum Ehrenberg, Pσrphyridium sp. UTEX 637 or a strain derived from Porphyridium sp. UTEX 637, Porphyridium cnientum UTEX 161 or a strain derived from Porphyridium omentum UTEX 161, Porphyridium aerugineurn or a strain derived from Porphyridium aerngineum, Porphyridium sordidum or a strain derived from Porphyridium sordidum, or Porphyridium purpureum or a strain derived from Porphyridium purpureum) is a unicellular red (Rhodophyta) microalga, with cells of 10-20 μM in diameter. Its habitats include fresh water, brackish water, sea water and soil, and it can grow under harsh climate conditions and high UV exposure.
- During the processing of the algae polysaccharide, the algae biomass (the algae cells) is removed while the secreted polysaccharide is retained. The precipitated algae biomass is sometimes considered a waste product, which is discarded during the production of the polysaccharide. The algae is rich in xanthine derivatives, which are sometimes extracted from the biomass for nutritional uses. In other times the algae pigments are extracted from the biomass.
- It was unexpectedly found that dried Porphyridium biomass has hydrogen peroxide degrading and eliminating activity (see Example 1). Moreover, exposure of human keratinocytes to dried Porphyridium biomass results in an enhancement of the endogenous cellular activity of the keratinocytes in degrading and eliminating hydrogen peroxide (see Example 2). These results suggest that dried Porphyridium biomass could be used topically, on skin, scalp, nail and hair, to reduce hydrogen peroxide concentration and provide beneficial effects. The topical use of dried Porphyridium biomass should slow, delay and reduce the progression of hair graying. Similarly, the topical use of dried Porphyridium biomass should reduce the visibility of depigmented skin lesions, and could reduce the signs of skin, scalp, hair, and nail aging and enhance elderly skin properties. It is expected that other plants of the family Porphyridiaceae, or of the Phylum Rhodophyta and not only those from the genus Porphyridium, would have similar biological properties and could also be used in a similar manner. Non-limiting examples of other red microalgae suitable for this disclosure include the unicellular algae of the Bangiophyceae, Florideophyceae, Goniotrichales, Dixoniella grisea, or other member of the Rhodophyta.
- The precise concentrations, effects of the composition and methods of this disclosure will vary with the area being treated, the age, health and skin and hair type of the end user, the duration and nature of the treatment, the specific composition employed, the particular condition being treated, the particular cosmetically- or pharmaceutically-acceptable carrier utilized, and like factors.
- The present disclosure describes a natural extract(s) or their fraction(s), or combination(s) thereof (1) containing active, non-denatured catalase, or (2) having a catalase-like activity, or (3) having a catalase-enhancing activity, or (4) having a catalase-stabilizing activity, or mixtures thereof. The natural extract described in this disclosure can be, but is not limited to, a plant extract, an algae extract, a yeast extract, a fungi extract, a microorganism extract, or a fraction(s) of such extract(s), or combinations thereof.
- The natural extracts of this disclosure are aqueous. Aqueous extracts are materials that were extracted by any solvent consisting totally or partially of water, including, but not limited to water itself, aqueous/alcoholic solvents in any proportion, or solvents comprising water and a compound such as propylene glycol, in any proportion. The aqueous extract could be in a liquid form or could be dried out to a solid form.
- When the aqueous extract is dried
- In one instance, an enhancement of catalase production within the natural source is achieved by (1) selecting relevant genetic variants, or (2) using genetic engineering technologies, or (3) controlling a timed and selective exposure (e.g. continuous, pulsed, at a defined growth phase) to hydrogen peroxide, or (4) controlling a timed and selective exposure to different wavelengths (e.g. UV, blue, or others), or (5) providing certain ingredients (e.g. chemicals, nutritional agents) that affect the growth or the biological properties of the natural source, before collecting the natural source for extraction, or combinations thereof.
- In another instance, the natural source (1) could be grown under nutritional conditions that enrich for L-methionine, or (2) could be grown under nutritional conditions that enhance the production of L-methionine, or (3) could be supplemented with L-methionine during growth, or (4) could be engineered to produce or retain L-methionine, or (5) could be combined with L-methionine during the preparation and processing of the natural extract. The L-methionine enriched extract could be used in all the compositions and methods disclosed herein, and is expected to have superior effects in reducing hydrogen peroxide concentrations in skin, scalp, hair and nail. In one example the fertilization of plants is performed with a micronutrient composition that includes high levels of L-methionine. Another example relates to the enrichment of the growth medium of algae, fungi, yeast and other microorganisms with about 0.1-100 mM L-methionine, which can lead to increased methionine in the extracts prepared from these materials. In addition or as an alternative, the natural extract (e.g. Amor Seco leave powder, Yacón leave powder or dried Porphyridium biomass, or their aqueous extracts) can be combined with 0.1-100 mM of L-methionine, at any stage of the natural extract production and processing.
- The effective concentration of L-methionine in the composition should be about the same as the concentration of hydrogen peroxide within the affected tissue (e.g. the graying hair follicle, the vitiligo lesion, the elderly skin, and the like). This concentration varies with the age, gender, skin type and hair type of the individual, and with their specific need (e.g. hypo-pigmented lesions, gray hair, elderly skin, and the like). Lower concentrations (high micromolar range) would be effective for geriatric skin, while higher concentrations (low milimolar range) would be required for affecting gray hair and hypo-pigmentary skin lesions.
- In another instance, the natural extracts of this disclosure are non-denatured, and contain stable and active proteins like the catalase enzyme or the glutathione peroxidase enzyme. “Denaturation” is defined in the Bantam Medical Dictionary (1990 edition) as “the change in the physical and the physiological properties of a protein, that are brought about by heat, X-rays or chemicals. These changes include loss of activity in the case of enzymes”. What is meant by “non-denatured product” is a natural product in which the processing for the derivation of such product (e.g., the temperature, extraction media) did not eliminate its specific hydrogen peroxide elimination activity.
- In yet another aspect, extracts of this disclosure could be further purified, or concentrated or fractionated or combined to increase the content of the catalase enzyme or the glutathione peroxidase enzyme or the catalase-like activity.
- Awareness to environmental concerns has increased, and “green” considerations are incorporated into products and disclosures. In one instance, the natural sources of this disclosure would consist of unused or “wasted” natural products. Examples for such sources include, but are not limited, to leaves and stems that are not collected in the field, or are collected and then separated, when fruits, vegetables, roots and grains are harvested, and might be otherwise discarded or provided for animal feed. Other examples include plants parts that are removed during food processing, like legume pods or fruit and vegetable peels. Another example includes botanical parts that are removed during the processing or production of specific botanical products, such as the algae biomass that is removed during the production of the algae polysaccharide.
- Extracts of this disclosure can be tested for their hydrogen peroxide eliminating activity using colorimetric or spectrophotometric assays such as the Catalase Assay Kit of Cayman Chemical (#707002), the BioVision Inc. Catalase Activity Colorimetric/Fluorometric Assay Kit (#K773-100), The Sigma Aldrich Enzymatic Assay of Catalase (EC 1.11.1.6) kit, the AmplexAE Red Catalase Assay Kit (#A22180) of Molecular Probes, or the like. Such assays are sensitive to detect pico units of catalase activity within samples. The catalase enzyme itself can also be detected and quantified within the extracts using standard procedures, however the existence of the protein does not guarantee its activity, and therefore the activity assays are preferred, and are used to define the natural extracts.
- In another instance, the natural extracts of this disclosure contain catalase-like activity, namely the ability to degrade or eliminate hydrogen peroxide, directly or indirectly, without containing an intact catalase or glutathione peroxidase enzyme. In one aspect, such extracts could be further concentrated, or purified, or fractionated, or combined to increase the content of the catalase-like activity. In another aspect, such extracts could be tested for their hydrogen peroxide eliminating activity using similar assays to those describe above, as such assays are measuring the reaction products and not the enzyme concentrations. Such extracts could be defined, therefore, by their hydrogen peroxide eliminating activity.
- Topically applied agents of relatively large molecular weight have the potential to reach pharmacologically active concentrations at the hair bulb, if properly formulated with adequate delivery vehicles. The delivery occurs via the junction of the internal and external root sheath, and the higher molecular weight molecules are confined to the follicular structures immediately surrounding the hair shaft. (J Pharm Sci. 1997 86(9):1022-9. Description of the intrafollicular delivery of large molecular weight molecules to follicles of human scalp skin in vitro. Lieb L M, Liimatta A P, Bryan R N, Brown B D, Krueger G G). However, it is desired sometimes to have active ingredients of smaller molecular weight delivered to the hair follicles, or directly to the skin, to increase and enhance their effective concentrations and their efficacy. In yet another example, the natural extracts containing catalase-like activity of this disclosure could be size fractionated and selected, and then concentrated, or combined, to increase the concentration of smaller molecular weight ingredients with the desired activity within the composition. In one aspect, the molecular weight of the ingredients having the desired activity is smaller than that of catalase. In another aspect, the molecular weight of the ingredients having the desired activity is smaller than 1 kDa. The size of ˜0.5 kDa is considered the largest for passive skin penetration (Bos J D, Meinardi M M H M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000 9:165-16)]. In yet another aspect, the molecular weight of the ingredients having the desired activity is smaller than ˜0.5 kDa.
- The natural extract of this disclosure could enhance the gene expression, or the protein translation, or the stability, or the activity of the endogenous catalase enzyme or the endogenous glutathione peroxidase enzyme in the skin, or the nail, or the hair follicle. In one aspect, such extracts could be further concentrated, or purified or fractionated or combined to enhance such an activity. In one aspect, such extracts could be defined by their hydrogen peroxide eliminating activity.
- In yet another example, extracts of this disclosure that enhance the expression, or the stability, or the activity of the endogenous skin, scalp, nail, or hair follicle catalase enzyme and/or glutathione peroxidase enzyme, could be size fractionated and selected, and then concentrated, or combined, to increase the concentration of smaller molecular weight ingredients with the desired activity in the composition. In one aspect, the molecular weight of the ingredients that enhance the expression, or the stability, or the activity of the endogenous skin, nail, scalp or hair follicle catalase and/or glutathione peroxidase enzyme is smaller than that of catalase. In another aspect, the molecular weight of the ingredients that enhance the expression, or the stability, or the activity of the endogenous skin or hair follicle catalase and/or glutathione peroxidase enzyme is smaller than 1 kDa. In yet another aspect, the molecular weight of the ingredients that enhance the expression, or the stability, or the activity of the endogenous skin or hair follicle catalase and/or glutathione peroxidase enzyme is smaller than 0.5 kDa.
- The natural extracts of this disclosure can be evaluated for their catalase and/or glutathione peroxidase enhancing activity in skin, scalp, hair or nail or in their relevant in vitro systems. Such in vitro systems include, but are not limited to epidermal, or dermal, or epidermal-dermal skin constructs that can be obtained commercially, e.g. from MatTek corporation, monolayers of melanocytes, epidermal keratinocytes, dermal fibroblasts or follicular keratinocytes that can be obtained commercially, e.g. from ATTC, skin explants with and without hair that can be obtained from e.g. human and animal biopsies, cultured hair plugs, and the like. An example of such an assay includes the incubation of the biological samples with and without the extracts of this disclosure, using a range of safe and effective concentrations, for different time points (e.g. 24, 48 and 96 hours). The biological samples can be homogenized and tested for hydrogen peroxide elimination activity using the assays described above, or they can be tested for irritation biomarkers, sensitization biomarkers, inflammatory responses, anti-oxidant responses and the like using known procedures. Additionally, they can be tested for the enhanced expression or stability of the endogenous catalase and/or glutathione peroxidase enzyme, or of other cellular anti-oxidant enzymes, using standard molecular procedures. Additionally, the biological samples can be challenged (e.g. with UV irradiation or hydrogen peroxide exposure) and their viability and their biological responses and catalase and/or glutathione peroxidase expression and activity can be evaluated using known and validated assays for e.g. catalase and/or glutathione peroxidase expression or activity, irritation, sensitization, inflammatory responses, anti-oxidant responses and the like. Viability can be evaluated with e.g. a standard MTT assay. Irritation and inflammatory responses can be evaluated e.g. by measuring the release of inflammatory cytokines such as IL-1 alpha into the culture media, using standard ELISA techniques. Anti-oxidant responses can be measured with standard assays e.g. using ABTS (trolox equivalent) or DPPH kits. Catalase and/or glutathione peroxidase expression and stability can be evaluated using standard techniques such as QPCR or protein immune-reactivity over time.
- The novel compositions of this disclosure contain aqueous natural extracts, which might be present in many forms such as of a fluid or a solid. In one example, the aqueous natural product is in the form of a suspension. One way to make the natural suspension is to soak the fresh or dry natural sources in a liquid (e.g. water) for from about 10 minutes to several hours, and after they were fully hydrated to press, or grind them, to allow the ingredients to be extracted. Procedures such as pressure disruption, sonication and milling (e.g., jet milling and ball milling, sometimes performed under cold or freezing conditions) can be used instead of grinding, to break down the biological material for improved extraction. The suspension may be filtered to remove any residual parts. In one example the suspension is filtered using a 0.2 micron pore size filter. The natural suspension could be dried by e.g. tray drying, spin drying, rotary drying, spin flash drying, or lyophilization.
- Another example is to press the natural sources and collect the “juice” created by the pressing of the natural material. After collection, the suspension may be filtered to remove any residual parts. In one instance the suspension is filtered using a 0.2 micron pore size filter. The natural suspensions and solutions used in this disclosure can use fresh natural sources, or may be made from dry, powdered natural sources and liquid. The powder is milled (e.g. by pressure disruption, sonication, jet milling or ball milling and the like) from the natural sources (e.g. botanical parts, algae, fungi or microorganism cultures and the like) and may also be dried (e.g. lyophilized, spin-dried, spray dried, tray dried, spin flash dried, freeze-dried and the like) and the resulting powder may or may not be filtered. In one example the suspension or solution is filtered using a 0.2 micron pore size filter. Such prepared suspension or solutions may have from about 0.01 to about 90% by weight dry powder.
- Another example is the use of natural extract powder, made from, e.g. lyophilized, spray dried or freeze-dried suspension as described above and the like, with the addition of liquid and with or without filtration or homogenization.
- Other known methods of extraction could also be used to create the active ingredients used in this disclosure. For example, but not limited to, the active ingredients could be extracted from ground natural sources using ethanol/water mixtures, followed by the removal of the ethanol from the extract, in such ways that the specific catalase and/or glutathione peroxidase activity or catalase-related activity of the preparation will be retained. Known methods of fractionation could be used to separate and concentrate the desired activities of this disclosure, or to size fractionate the natural extract, or to eliminate inhibitory or undesired activities. In one example, the natural extracts of this disclosure could be produced using electro-kinetic potential (Zeta) fractionation and separation (e.g. with the Zeta Fraction™ Technology (http://www.sc.akzonobel.com/en/personalcare/Pages/zeta-fraction.aspx)). Zeta Fraction technology can selectively isolates intracellular components from biological sources, e.g. from plants “juices”, without the use of external solvents for separation. Targeted fractions with active catalase and/or glutathione peroxidase, or with catalase-like activity, could be mechanically separated based on their electro-kinetic (zeta) potential, to be used in compositions of this disclosure. The zeta fractions could be further processed (e.g. filtered, dried, combined) as described above.
- Yet in another example, the fresh or dry natural source of this disclosure could be grinded or milled as described above, suspended in a liquid (e.g. water) and then undergo a mechanical homogenization, or a particle-size reduction (e.g. by sonication, or shear mixing, or homogenization, or any other known semi solid processing, sometimes performed under cold or freezing conditions) to create a homogenate (so that the cells or biomass of the natural source are broken or disrupted). The resulting suspension could then be separated (e.g. by centrifugation of e.g. 500-1,000 RPM for 10 minutes, or by similar procedures), and the supernatant could be further size-selected (e.g. for particles of the size of 0.2 micron or smaller, e.g. by size filtration membranes, ultra-filtration and the like). The resulting suspension or solution of, e.g., 0.2 micron size particles or smaller could be used for the compositions of this disclosure “as is”, or could be dried-out using standard procedures (e.g. lyophilized, spin-dried, spray dried, tray dried, spin flash dried, freeze-dried and the like) to create a more refined natural extract. All such processes should not create unreasonable heat that might reduce or eliminate the biological activity of the natural extract.
- Useful compositions can include stabilization systems, which may include one or more preservatives, or one or more anti-oxidants, or one or more chelating agents, or combinations thereof. Preservatives are useful for substantially preventing microbial decomposition. Examples of preservatives include, but are not limited to phenoxyethanol, parabens and natural preservatives, and are known to the ones skilled in the art. Other examples of preservatives could be found on pages 1654-55 of the International Cosmetic Ingredient Dictionary and Handbook, eds. Wenninger and McEwen (CTFA, 7th ed., 1997), hereinafter referred to as the “Cosmetic Handbook.” The composition may comprise from about 0.01% to about 20%, by weight (sometimes more preferably, from about 0.5% to about 5%, by weight) of preservative. Microbial contamination can also be eliminated by gamma irradiation, or electron-beam irradiation, or X-ray irradiation and the like, by microfiltration, or by other standard procedures (e.g. brief heat treatments) that do not result in the elimination of the specific activity described in this disclosure.
- Antioxidants and/or chelating agents may also be used to increase shelf life and stability of the compositions. Antioxidants may be added both for formulation stabilization and for biological efficacy. Antioxidant compounds and their derivatives include, but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cystein), lipoic acid and dihydrolipoic acid, resveratrol, acetyl-cysteine (Iniferine®) or lactoferrin, and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbyl polypeptide). Oil-soluble antioxidants suitable for use in the compositions of this disclosure include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol acetate), tocotrienols, and ubiquinone. Natural extracts containing antioxidants suitable for use in the compositions of this disclosure, include, but are not limited to, extracts containing flavonoids and isoflavonoids and their derivatives (e.g., genistein and diadzein), extracts containing resveratrol, extracts containing polyphenols and the like. Examples of such natural extracts include, but are not limited to, grape seed, tea, pine bark, Aloe Vera, propolis, or legume extracts. Small molecules with specific antioxidant activity, including, but not limiting to catalase mimetics, SOD mimetics, salem-Mn complexes (e.g. the EUK family of compounds), and the like, are also suitable for use in compositions of this disclosure. Other examples of antioxidants may be found on pages 1612-13 of the Cosmetic Handbook. The compositions of the present disclosure may comprises the antioxidant in an amount of from about 0.001% to about 20%, by weight (e.g., from about 0.01% to about 10% by weight) of the composition.
- Chelating agents are also useful in assisting the stabilization of compositions. Examples of chelating agents include, but are not limited to EDTA and derivatives thereof (e.g., disodium EDTA and dipotassium EDTA), Iniferine lactoferrin, and citric acid. Other examples of chelating agents are listed on page 1626 of the Cosmetic Handbook. The compositions of the present disclosure may comprise the chelating agent in an amount of from about 0.001% to about 20%, by weight (e.g., from about 0.01% to about 10% by weight) of the composition.
- Thickening agents (e.g., thickeners or viscosity enhancing agents) may be used to alter the viscosity of useful compositions. The desired viscosity of the composition will depend upon the intended use (e.g., as a shampoo, conditioner, mousse, cream, lotion, ointment, serum, spray, gel, stick, or the like). For example, in applications such as bath or wash products, the viscosity of the composition should be relatively low, similar to an aqueous solution. Application as a cream, lotion, or gel will have slightly higher viscosity (e.g., between about 100 cps and 100,000 cps). Thickening agents that can be added to the compositions of this disclosure to alter viscosity include polymers such as sepigels or polyacrylates (e.g., polyacrylamide, other carbomers) or polysaccharides (e.g. chitosan). Other examples of viscosity modifying agents are listed on pages 1692-97 of the Cosmetic Handbook. To achieve the appropriate viscosity, compositions of the present disclosure may comprise from about 0.01% to about 20%, by weight (e.g., from about 0.1% to about 5%, by weight) of a thickening agent.
- The compositions containing natural extracts can also contain other cosmetically active agents (e.g., a synthetic compound(s) or a compound(s) isolated from a natural source, or a natural extract(s) containing a mixture of compounds that has a cosmetic or therapeutic effect on the tissue). The useful compositions described herein may also contain other skin-, hair- and nail-beneficial agents in addition to the natural product(s). Examples of such agents include, but are not limited to, anti-inflammatory agents (such as corticosteroids, NSAIDs, or botanical extracts with anti-inflammatory activity such as Aloe Vera), anti-pruritic agents, topical analgesics, antioxidants (e.g. vitamin C and derivatives, vitamin E and derivatives, botanical extracts with antioxidant activity), agents with catalase-like or SOD-like activity (e.g. salem MN compounds such as the family of EUK agents), epidermal-, dermal- and follicular-regenerating agents and agents that enhance skin, hair and nail tissue regeneration agents (including e.g. retinoids, retinoid-derivatives, retinol, retinal, alpha hydroxy acids, co-enzyme-Q, growth factors, and others), antibiotics and anti-microbial agents, anti-mycotic agents, anti-yeast agents, anti-parasites, agents that enhance the immune system, dandruff-control and shine-control agents (including e.g. miconazole, ketoconazole, elubiol, itraconazole, coal tar and the like agents), detergents, surfactants, moisturizers, nutrients, vitamins, minerals, energy enhancers, hair or nail growth enhancing agents, agents that delay hair growth, agents for skin conditioning, odor-control agents (such as e.g. odor masking or pH-changing agents), deodorants, antiperspirants, colorants, pigments, color-masking agents, agents that enhance pigment production or pigment delivery (e.g. such as peptides, PAR-2 activators, MC1R ligands, alpha MSH and its mimetics, and the like), agents that enhance or inhibit pigment production, agents that affect methionine sulfoxide reductase activity (e.g. L-methionine, that could prevent the oxidation of methionine) and other agents that enhance skin, scalp, hair or nail wellness and beauty that are known to those of ordinary skill in the art.
- The useful compositions described herein may also contain compounds that enhance the feel of the composition on the skin, scalp, hair or nail of the user. Examples of such compounds include, but are not limited to, oils, silicones (e.g., siloxane polymers such as dimethicone), polymers, polysaccharides, and skin-conditioning agents such as emollients, and humectants. Some examples of such skin conditioning agents may be found of pages 1656-1670 of the Cosmetic Handbook. In addition, the compositions useful herein can contain conventional cosmetic adjuvants, such as colorants (such as dyes and pigments), opacifiers (e.g., titanium dioxide), and fragrances, which are known to those skilled in the art in the field of this disclosure. The composition and formulations containing such compositions of the present disclosure may be prepared using methodology that is well known by an artisan of ordinary skill.
- The compositions of this disclosure may be used, but are not limited to, with cosmetically or pharmaceutically accepted forms and carriers such as solutions, suspensions, emulsions (including microemulsions and nanoemulsions), lotions, creams, gels, sticks, sprays, ointments, cleansing liquids, washes, solid bars, shampoos, hair conditioners, nail polishes, nail strengtheners, pastes, foams, powders, mousses, shaving creams, shaving gels, wipes, patches, hydrogels, film-forming products, masks, liquid drops, muco-adhesives, and the like. The compositions of this disclosure may be packaged in a tube, a sealed packet, a jar, a pump, a bottle, a can, a pledget, a towelet, a dispenser, a wipe, a spray can or the like. An airtight or a light-blocking package (e.g. such as an aluminum tube, aluminum pocket, pump, or laminated tube), can also be used to further enhance product stability.
- In one aspect, the compositions of this disclosure further comprise of delivery systems that enable to maintain an active catalase and/or glutathione peroxidase enzyme or catalase-related activity, and deliver the active ingredients, possibly including active proteins, into the hair follicles, or into the nail, or into the skin. Such delivery systems may include micro- and nano-particles, liposomes, aspasomes, organogels, niosomes, transferosomes, patches, micro- and nano-needles, micro- and nano-capsules, micro- and nano-sponges, films, polymers, and the like.
- The present disclosure features a method of reducing the hair graying process of a mammal, said method comprising the step of applying to the scalp or to other desired non-glabrous skin areas a safe and effective amount of the compositions of this disclosure. The frequency of the application will vary with the area being treated, the age, health, hair type and skin type of the end user, the duration and nature of the treatment, the specific composition employed, the particular cosmetically- or pharmaceutically-acceptable carrier utilized, and like factors. For example, in some instances the application would be periodic, while in other instances the application would be once or twice daily.
- Additionally, the present disclosure features a method of reducing non-pigmented lesions on the skin of a mammal (e.g. of an age-induced or UV-induced pigment loss spots, or IGH, or vitiligo), said method comprising the step of applying to the skin areas a safe and effective amount of the compositions of this disclosure. The frequency of the application will vary with the area being treated, the age, health and skin type of the end user, the duration and nature of the treatment, the specific composition employed, the particular cosmetically- or pharmaceutically-acceptable carrier utilized, and like factors. For example, in some instances the application would be periodic, while in other instances the application would be once or twice daily. Additionally, the present disclosure also features a method of reducing the signs and symptoms of skin, scalp, hair and nail aging and enhancing the biological properties and the health and wellbeing of geriatric skin, said method comprising the step of applying to the skin, scalp, hair or nail areas in need a safe and effective amount of the compositions of this disclosure. The frequency of the application will vary with the area being treated, the age, health and skin type of the end user, the duration and nature of the treatment, the specific composition employed, the particular cosmetically- or pharmaceutically-acceptable carrier utilized, and like factors. For example, in some instances the application would be periodic, while in other instances the application would be once or twice daily.
- As used herein, “safe and effective amount” means an amount of the composition sufficient to induce a desired effect on hair, nail or skin, but low enough to avoid serious side effects. The safe and effective amount of the composition will vary with the area being treated, the age, health, hair type and skin type of the end user, the duration and nature of the treatment, the specific composition employed, the particular cosmetically- or pharmaceutically-acceptable carrier utilized, and like factors.
- It is understood that while the disclosure has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the disclosure.
- This study evaluated the hydrogen peroxide breakdown activity of test agents. A Catalase assay kit was obtained from Cayman Chemical Co. (Ann Arbor, Mich.). The assay measures hydrogen peroxide elimination activity (e.g. catalase activity) using Purpald (4-amino-3-hydrazino-5-mercapto-1,2,4-triazole) as chromogen in a colorimetric assay. The testing involves the changes in optical density (OD) at 540 nm, which is proportional to the effective activity present in the sample based on the reaction with methanol in the presence of hydrogen peroxide. Purpald, used as chromogen, forms a bicyclic heterocycle with the formaldehyde produced, which upon oxidation changes from colorless to purple color.
- Sample powders of the naturals were suspended in water or PBS at 5% (w/v), sonicated to break the material to sub-micron particles, homogenized, and centrifuged at 1,000 RPM for 10 min to remove insoluble material. Serial dilutions were prepared for each test material and mixed with methanol and hydrogen peroxide in assay buffer solution. Reaction was set for 20 minutes at room temperature. All samples were compared to assay buffer-treated samples (used as negative control). Catalase enzyme standard, derived from bovine liver, was used as positive control. Optical density changes at 540 nm were evaluated after addition of potassium hydroxide, Purpald and potassium periodate.
- The results of this study are shown in Table 1. These results show that the dry leave powders of Amor Seco and Yacon and the dried Porphyridium biomass possess high hydrogen peroxide eliminating activity.
- As a reference and for comparison, the literature (Nadira Binte Samad, Trishna Debnath, Michael Ye, Abul Hasnat, Beong Ou Lim. In vitro antioxidant and anti-inflammatory activities of Korean blueberry (Vaccinium corymbosum L.) extracts. Asian Pac J Trop Biomed 4(10): 807-815 (2014)) refers to two Korean blueberry (Vaccinium corymbosum L.) leaf extracts that are known to have strong antioxidant activities. These extracts were documented to have catalase activity of up to 0.67 nmol/min/ml at 0.33% (w/v). In contrasts, the natural extracts of this disclosure, at a lower (0.1% w/v) concentration, had their activity ranges from 1.5-2.5 nmol/min/ml.
-
TABLE 1 Hydrogen peroxide elimination activity of test agents Yacon leave powder Amor Seco leave powder Dried Porphyridium biomass Formaldehyde Activity Formaldehyde Activity Formaldehyde Activity Agent [μM] [nmol/min/mL] [μM] [nmol/min/mL] [μM] [nmol/min/mL] (w/v) (Avg ± StDev) (Avg ± StDev) (Avg ± StDev) (Avg ± StDev) (Avg ± StDev) (Avg ± StDev) 0.001% 36.8 ± 22.6 1.8 ± 1.1 29.8 ± 13.9 1.5 ± 0.7 21.2 ± 1.0 1.1 ± 0.1 0.01% 23.5 ± 5.6 1.2 ± 0.3 32.7 ± 9.6 1.6 ± 0.5 17.1 ± 2.0 0.9 ± 0.1 0.05% 20.0 ± 4.6 1.0 ± 0.2 31.0 ± 11.2 1.5 ± 0.6 44.3 ± 12.8 2.2 ± 0.6 0.1% 31.0 ± 16.5 1.5 ± 0.8 56.4 ± 21.3 2.8 ± 1.1 53.5 ± 18.1 2.7 ± 0.9 0.5% 42.6 ± 16.5 2.1 ± 0.8 92.3 ± 8.7 4.6 ± 0.4 * * 1% 61.6 ± 23.9 3.1 ± 1.2 144.9 ± 18.7 7.2 ± 0.9 * * 5% 188.3 ± 22.0 9.4 ± 1.1 550.2 ± 20.8 27.5 ± 1.0 * * (*) The red-brown color of this natural extract, at higher testing concentrations, was stronger than the Purpald red-purple readout color, and therefore prevented an accurate reading of the results.
These results indicate that the dry leave powders of Amor Seco and Yacon and the dried Porphyridium biomass have high hydrogen peroxide eliminating activity, and therefore they are suitable, at concentrations of from about 0.001% (w/v) and higher, for use in the topical preparations of this disclosure. - This study evaluated the effect of test materials on the endogenous cellular hydrogen peroxide degrading and eliminating activity of cultured normal human keratinocytes. Protein lysates of treated cells were used to measure hydrogen peroxide degrading activity using Purpald (4-amino-3-hydrazino-5-mercapto-1,2,4-triazole) as chromogen in a colorimetric assay. The testing involved the changes in optical density (OD) at 540 nm, which is proportional to the effective activity present in the sample based on the reaction with methanol in the presence of hydrogen peroxide. Purpald, used as chromogen, forms a bicyclic heterocycle with the formaldehyde produced, which upon oxidation changes from colorless to purple color. Sample powders of the natural test agents were suspended in phosphate buffer (1× PBS) at 5% w/v, and were homogenized by sonication. Following a 1,000 RPM spin for 10 minutes, the supernatants were sterilized by filtration using a 0.2 μm syringe filter, as described in Example 1. The samples (sonicated filtered supernatants of the 5% suspensions) were then serially diluted to the desired test concentrations. Primary normal human epidermal keratinocytes (NHEKs) were seeded on 6-well plates and cultured for 24 hours. Subsequently, cells were treated with or without test materials, at 0.005, 0.05 and 0.5% (concentrations refer to the original 5% suspensions) in culture media, once daily, for 3 days. Cells were harvested on the 4th day and then lysed and total protein concentrations in the lysates were measured using the BSA-Bradford assay. Cell lysates were mixed with methanol and hydrogen peroxide in assay buffer. Reaction was set for 20 minutes at room temperature. All samples were compared to assay buffer-treated cells (used as negative control). Catalase enzyme standard, derived from bovine liver, was used as positive control. Optical density changes at 540 nm were evaluated after addition of potassium hydroxide, Purpald and potassium periodate. For the assay, average absorbance was calculated and subtracted from the negative control for each sample and standards.
- The results of this study are shown in Table 2. These results show the hydrogen peroxide degrading activity induced by each test agent within the treated keratinocytes, as compared to the endogenous activity of the untreated keratinocytes. All test materials produced a dose-responsive increase in the keratinocyte endogenous activity of hydrogen peroxide elimination. The untreated keratinocytes showed an activity of 1.5±0.2 Unit/mg protein (U/mg), and the test agents, at 0.5% (w/v), were able to increase this activity up to more than 210% (3.2±0.1 (U/mg)).
- As a reference and for comparison, a Camellia japonica extract with a strong antioxidant activity, at 0.005%, was reported to enhanced catalase activity of HaCaT keratinocytes by about 50% only, and an ethanolic fraction of Sargassum muticum extract, at 10%, enriched for anti-oxidant activity, enhanced HaCaT cells catalase activity by 25% only [Antioxidant Effects of the Ethanol Extract from Flower of Camellia japonica via Scavenging of Reactive Oxygen Species and Induction of Antioxidant Enzymes. Mei Jing Piao, Eun Sook Yoo, Young Sang Koh, Hee Kyoung Kang, Junoh Kim, Yong Jin Kim, Hak Hee Kang and Jin Won Hyun, Int. J. Mol. Sci. 2011, 12:2618-2630), (Protective Effect of the Ethyl Acetate Fraction of Sargassum muticum Against Ultraviolet B—Irradiated Damage in Human Keratinocytes. Mei Jing Piao, Weon Jong Yoon, Hee Kyoung Kang, Eun Sook Yoo, Young Sang Koh, Dong Sam Kim, Nam Ho Lee and Jin Won Hyun, Int. J. Mol. Sci. 2011, 12:8146-8160).
-
TABLE 2a Catalase Assay measurements Test Group Activity/total protein (U/mg) Catalase enzyme 8.6 ± 0.6 (positive control) Untreated cells 1.5 ± 0.2 (negative control) -
TABLE 2b Cellular hydrogen peroxide elimination, activity of test agents/total protein (U/mg) Test Material Yacon leave Amor Seco leave Dried Porphyridium (%, w/v) powder powder biomass 0.005 1.5 ± 0.1 2.0 ± 0.3 2.7 ± 0.1 0.05 1.8 ± 0.1 2.1 ± 0.4 3.0 ± 0.1 0.5 2.6 ± 0.1 2.5 ± 0.2 3.2 ± 0.1
The activity (U) is defined as nmol/min/mL. The activity is normalized to the total protein amount in each cell lysate sample, which is defined as U/mg. - These results show that exposure of human keratinocytes to Yacon leave powder, or Amor Seco leave powder, or dried Porphyridium biomass powder, results in an enhancement of the endogenous cellular activity of the keratinocytes, increasing their ability to remove, degrade or eliminate hydrogen peroxide. These results suggest that these agents could be used topically, for skin, scalp, hair and nail, to reduce hydrogen peroxide concentration, and therefore to be useful in this disclosure. The topical use of either Yacon leave powder, or Amor Seco leave powder or dried Porphyridium biomass powder, should slow, delay and reduce the progression of hair graying, which is initiated and enhanced by high endogenous hydrogen peroxide levels. Similarly, the topical use of Yacon leave powder, or Amor Seco leave powder, or dried Porphyridium biomass, should reduce the progression and the visibility of depigmented skin lesions, the signs of skin, scalp, hair, and nail aging, and the problems associated with geriatric skin.
- The purpose of this study was to evaluate intracellular antioxidant activity of test materials in cultured human epidermal keratinocytes, in response to a hydrogen peroxide insult. Cells were treated with test materials, labeled with H2DCFDA and later exposed to hydrogen peroxide. Relative fluorescence was measured as indicator for intracellular reactive oxygen species (ROS). The testing involved changes in fluorescence, which is proportional to an effective intracellular antioxidant activity when comparing untreated and hydrogen peroxide-only treated samples.
- Test agents were stored at room temperature until use. Sample powders were suspended in phosphate buffer (1× PBS) to make 10 mg/mL (1% w/v) stock solutions, vortexed for 1 minute, sonicated on ice for 10 minutes at 30-50% output, centrifuged at 1000 rpm for 10 minutes at 4° C., and the supernatants were sterilized using 0.2 μm-syringe filter. Such homogenized solutions were prepared for each test material.
- Primary normal human epidermal keratinocytes (NHEKs) were seeded on 96-well plates and cultured until reaching 75-80%. Subsequently, cells were treated with or without test materials in culture media for 24 hours. Test materials were created by diluting (1:10) the stock solutions in fresh EpiLife medium to make 0.05 and 0.1% (w/v) final concentrations. Untreated cells received equal volume of fresh EpiLife medium without test materials. At 24 hours, cells were labeled with the cell-permeant 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) for 60 minutes and intracellular ROS levels were induced with hydrogen peroxide treatment (250 μM) for 30 minutes. Relative fluorescence at 492 nm (Excitation) and 535 nm (Emission) was measured using a plate reader.
- Average fluorescence was calculated for each sample and compared to untreated (no H2O2) cells used as negative control. Results produced by H2O2-only treated cells showed that hydrogen peroxide produced a significant increase in relative fluorescence indicating an increase in intracellular ROS levels.
- The results of this study are shown in Table 3. Amor Seco leave extract and Yacon leave extract produced a significant decrease in relative fluorescence when tested at 0.05% (w/v) and 0.1% (w/v). Amor Seco leave extract induced an intracellular anti-ROS activity with 92-100% inhibition. Yacón leave extract led to a 49-67% inhibition. The Porphyridium biomass extract could not be evaluated in this study, as its fluorescence analysis documented strong auto-fluorescence that masked the readout of this assay.
-
TABLE 3a Summary results of H2DCFDA fluorescence* % Relative Fluorescence (Sample/Untreated) Test Material Average SEM Untreated 100.0 0.7 H2O2 (0.25 mM) 251.9 9.5 H2O2 + Yacon (0.05%) 133.2 13.0 H2O2 + Yacon (0.1%) 156.6 15.1 H2O2 + Amor Seco (0.05%) 111.5 5.2 H2O2 + Amor Seco (0.1%) 94.7 3.6 *Data shown represent mean ± SEM of relative fluorescence from two independent experiments (same experimental design run at different dates) -
TABLE 3b Summary results of ROS inhibition* Average ROS Inhibition (%) Test Material Average SEM Yacon (0.05%) 66.8 10.4 Yacon (0.10%) 48.7 12.7 Amor Seco (0.05%) 92.3 3.0 Amor Seco (0.10%) 103.5 2.1 *Data shown represent mean ± SEM of ROS inhibition from two independent experiments (same experimental design run at different dates) - These results show that exposure of human keratinocytes to Yacon leave powder, or Amor Seco leave powder, results in an enhancement of the endogenous cellular ability to remove, degrade or eliminate hydrogen peroxide. These results suggest that these agents could be used topically, for skin, scalp, hair and nail, to reduce hydrogen peroxide concentration, and therefore to be useful in this disclosure. As previous results (Example 1 and Example 2) showed that the dried Porphyridium biomass increased catalase activity greater than Yacon or Amor Seco leave extracts, it is expected that the dried Porphyridium biomass would produce superior results in this assay too.
- The topical use of either Yacon leave powder, or Amor Seco leave powder or dried Porphyridium biomass powder, should slow, delay and reduce the progression of hair graying, which is initiated and enhanced by high endogenous hydrogen peroxide levels. Similarly, the topical use of Yacon leave powder, or Amor Seco leave powder, or dried Porphyridium biomass, should reduce the progression and the visibility of depigmented skin lesions, the signs of skin, scalp, hair, and nail aging, and the problems associated with geriatric skin.
- Combining the knowledge of these studies, it is expected that the topical treatment with the natural agents of this disclosure would deliver the hydrogen peroxide eliminating activity of the agents themselves, and would additionally enhance the endogenous hydrogen peroxide breakdown or elimination activity of the keratinocytes. The effectiveness of these agents is expected at concentrations of from about 0.001% (w/v of powdered natural) and higher.
- Preparation of natural extract gel formulations. Natural extracts can be prepared as liquid samples (suspensions) or as sample powders of the natural source that are suspended in water or phosphate buffer or other aqueous solutions, to make e.g. 10-100 mg/mL (1-10% w/v) stock suspensions. The suspensions should be mixed (e.g. vortexed) for e.g. 1-10 minute, and the natural material should then be size-reduced, e.g. at 4° C., to break down the cells (e.g. by pressure disruption, jet milling, ball milling, or sonication e.g. for 10 minutes at e.g. 30-50% output). Larger particles should then be separated (e.g. by centrifugation at 500-1000 rpm for 10 minutes at 4° C.), and the pellets should be discarded. The supernatants can be directly used in the formulation, or could undergo a further size selection (e.g. the suspension or solution can be filtered using a 0.2 micron pore size filter). The resulting homogenized solutions of the naturals could be directly used in the formulations, or could be further dried (e.g. lyophilized, spray dried or freeze-dried), and used in the formulation as dry powders.
- Limited examples of some gel compositions suitable for this invention are suggested in Tables 4. A preservative (e.g. Phenonip®, phenoxyethanol), and/or a chelating agent (e.g. Disodium EDTA), and/or a humectant (e.g. glycerin) could be added first to the natural extract (which is in a liquid form or a powder suspended in liquid, e.g. water). At this step it is also possible to further add to the natural extract mixture oil-soluble silicones, emollients, viscosity builders or emulsifiers (e.g. cyclomethicone, dimethicone, PolySorbate 20, Aluminum Starch Octyl Succinate, Sucrose Cocoate, PEG-6 Capric/Caprylic Triglycerides). It is suggested to prepare a second mixture of a thickener(s) (e.g. Sepigel®, PolyAquol 2W) along with an anti-oxidant (e.g. BHT). The two mixtures should then be combined and mixed until homogeneity. Other anti-oxidants (e.g. ascorbic acid, sodium ascorbyl phosphate, lactoferrin, or tocopherol) could then added to the combined mix and evenly mixed to form the resulting gel.
-
TABLE 4 Average % % % % % % % % standard CTFA name W/W W/W W/W W/W W/W W/W W/W W/W ranges Natural extract 87.3 89.29 96.33 96.3 95.9 96.4 0-100 (liquid) Natural extract 1.0 5.0 0-25 (powder) Deionized water 94.8 90.9 0-100 L-methionine 0.1 0.01 0.05 0.1 0-1 Phenoxyethanol 0.75 0.75 0.75 0.75 0.75 1.0 1.0 0-5 Glycerine 2.5 2.5 0-5 Cyclomethicone 2.0 0-5 Aluminum Starch 0.75 0-5 Ocetyl Succinate Sucrose Cocoate 1.0 1.0 0-5 PEG-6 3.0 3.0 0-5 Capric/Caprylic Triglycerides Disodium EDTA 0.1 0.1 0.05 0.05 0.05 0-1 Polyacrylamine/Laureth- 2.5 2.75 2.9 2.9 3.2 3.0 0-5 7/C13-14 Isoparaffin Ascorbic Acid 0.01 0-1 Butylated 0.1 0.01 0.05 0.05 0.1 0.05 0.05 0-1 Hydroxytoluene Polysorbate 20 0.5 0-2 PolyAquol 2W 3.5 3.0 0-6 - Preparation of natural extract oil-in-water formulations. The natural extracts can be prepared as in example 4. Two examples of oil-in-water emulsions are presented in Table 5. To prepare this type of formulation, the ingredients of the lipid phase should be combined and mixed at about 50-85° C., and then cooled to about 40-60° C. In a separate vessel, the thickener can be slowly combined with the aqueous natural extract or the powder natural extract reconstituted in water or an aqueous solution. After mixing for e.g. about ten minutes the rest of the aqueous phase ingredients can be added and mixed, and then heated to about the lowest possible temperature of the lipid phase. The two phases can then be combined, mixed for e.g. for about ten minutes, and cooled to room temperature. Additional active agents may be combined into both phases or after their mixing. The biological activity described in this disclosure should be monitored, as excessive heat could reduce the desired activity.
-
TABLE 5 Average % % standard Phase CTFA Name W/W W/W ranges OIL Cetearyl Glucoside 1.4 1.4 0.1-2.8 C12-15 Alkyl Benzoate 4.0 4.0 1-6 Octyl Hydroxystearate 1.0 1.0 0-5 Dimethicone 1.0 1.0 0-5 Cyclomethicone 1.0 1.0 0-5 Cetyl Alcohol 2.5 2.5 0-4 Butylated Hydroxytoluene 0.1 0.1 0-0.5 Octyl Methoxycinnamate 6.0 6.0 0-10 Vitamin E acetate 0.5 0.5 0-0.5 Tocopherol Acetate 0.5 0.5 0-0.5 AQUEOUS Glycerine 3.0 3.0 0-20 D-Pathenol 0.5 0.5 0-5 Disodium EDTA 0.1 0.1 0.01-1 Phenoxyethanol 0.7 0.3 0-1 L-methionine 0.1 0.05 0-1 Carbomer 0.35 0.3 0-3 Deionized Water 76.25 50-80 Natural extract in 77.5 0.001-90 liquid form Natural extract in 1.0 0.001-20 powder form Other cosmetic or 0 0.25 0-10 therapeutic agents - Preparation of natural extract water-in-oil formulations. The natural extracts can be prepared as in example 4. Two examples of water-in-oil formulations are presented in Table 6. To prepare this type of formulation the emollients (e.g. mineral oil) can be melted. The other oil phase ingredients can then be added and the mixture can be heated e.g. to about 75° C. to enable homogeneous mixing. The aqueous phase ingredients can be mixed separately and should be warmed to the lowest possible temperature of the liquid oil phase (while confirming the retaining of biological activity of the natural extract), and then the two mixture can be stirred until it congealed. Additional active agents may be combined into both phases or after their mixing.
-
TABLE 6 Average % % standard Phase CTFA Name W/W W/W ranges OIL Mineral Oil 25.0 25.0 40-80 Sorbitan Monooleate 5.0 5.0 1-6 Stearyl Alcohol 25.0 25.0 20-60 Dimethicone 1.0 1.0 1-5 Cetyl Alcohol 2.0 2.0 0.1-10 Hydrogenated Lecithin 3.0 3.0 0-10 Parsol MCX 3.0 3.0 0-10 Vitamin E acetate 0.5 0.5 0.01-0.5 AQUEOUS Glycerine 3.0 3.0 0-20 Phenoxyethanol 0.7 0.7 0.01-1 Deionized Water 30.79 20-45 Natural extract in 31.55 20-45 liquid form Natural extract in 1.0 0 0-10 powder form L-methionine 0.01 0-1 Other active agents 0 0.25 0-1 - It is understood that while the disclosure has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the disclosure.
Claims (1)
1. A method for reducing hair graying, comprising applying to scalp or non-glabrous skin a composition comprising an aqueous extract of (i) Yacon leave, (ii) Amor Seco leave, or (iii) Porphyridium biomass, or a combination thereof and a pharmaceutically or cosmetically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/895,990 US20200297608A1 (en) | 2015-11-18 | 2020-06-08 | Compositions containing natural extracts and use thereof for skin and hair |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562256803P | 2015-11-18 | 2015-11-18 | |
US15/342,947 US10675233B2 (en) | 2015-11-18 | 2016-11-03 | Compositions containing natural extracts and use thereof for skin and hair |
US16/895,990 US20200297608A1 (en) | 2015-11-18 | 2020-06-08 | Compositions containing natural extracts and use thereof for skin and hair |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/342,947 Continuation US10675233B2 (en) | 2015-11-18 | 2016-11-03 | Compositions containing natural extracts and use thereof for skin and hair |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200297608A1 true US20200297608A1 (en) | 2020-09-24 |
Family
ID=58689743
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/342,922 Active US10206861B2 (en) | 2015-11-18 | 2016-11-03 | Compositions containing natural extracts and use thereof for skin and hair |
US15/342,947 Active 2037-04-10 US10675233B2 (en) | 2015-11-18 | 2016-11-03 | Compositions containing natural extracts and use thereof for skin and hair |
US16/895,990 Abandoned US20200297608A1 (en) | 2015-11-18 | 2020-06-08 | Compositions containing natural extracts and use thereof for skin and hair |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/342,922 Active US10206861B2 (en) | 2015-11-18 | 2016-11-03 | Compositions containing natural extracts and use thereof for skin and hair |
US15/342,947 Active 2037-04-10 US10675233B2 (en) | 2015-11-18 | 2016-11-03 | Compositions containing natural extracts and use thereof for skin and hair |
Country Status (10)
Country | Link |
---|---|
US (3) | US10206861B2 (en) |
EP (1) | EP3377084A4 (en) |
JP (1) | JP7411327B2 (en) |
KR (1) | KR20180081602A (en) |
CN (1) | CN108472322A (en) |
AU (3) | AU2016357227A1 (en) |
CA (1) | CA3005842A1 (en) |
EA (1) | EA201891183A1 (en) |
HK (1) | HK1258675A1 (en) |
WO (1) | WO2017087177A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017132771A1 (en) * | 2016-02-03 | 2017-08-10 | Vida Therapeutics, Inc. | Granzyme b inhibitor formulations and methods for the treatment of burns |
CA3038327C (en) | 2016-10-03 | 2024-03-12 | Houn Simon Hsia | Compositions and methods for enhancing cancer radiotherapy |
US10905725B2 (en) | 2017-06-13 | 2021-02-02 | Houn Simon Hsia | Compositions and methods for enhancing cancer chemotherapy |
EP3638270B1 (en) | 2017-06-13 | 2023-10-25 | Houn Simon Hsia | Compositions and methods for enhancing hyperthermia therapy |
US12029765B2 (en) * | 2017-06-13 | 2024-07-09 | Houn Simon Hsia | Compositions and methods for treating cancer |
US11020340B2 (en) | 2017-09-18 | 2021-06-01 | Seiberg Consulting, LLC | Compositions containing natural products and use thereof for skin and hair |
JP2020090465A (en) * | 2018-12-06 | 2020-06-11 | 株式会社ミルボン | Method, composition and agent using apple young fruit extract |
CN110522698A (en) * | 2019-09-30 | 2019-12-03 | 广州香枝化妆品有限公司 | A kind of scalp injury repairs Essence and preparation method thereof |
KR102472857B1 (en) * | 2022-08-10 | 2022-12-01 | 임연재 | Hair treatment composition without washing |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0759548A (en) * | 1993-08-20 | 1995-03-07 | Tanabe Seiyaku Co Ltd | Natural antioxidant |
JPH0812552A (en) | 1994-06-29 | 1996-01-16 | Shiseido Co Ltd | Skin external preparation |
JP4176912B2 (en) | 1999-05-10 | 2008-11-05 | 一丸ファルコス株式会社 | Cosmetic composition containing moisturizing plant extract |
JP2002069443A (en) * | 2000-08-30 | 2002-03-08 | Microalgae Corporation | Antioxidant and cosmetic containing the antioxidant |
JP2002205950A (en) | 2001-01-10 | 2002-07-23 | Ichimaru Pharcos Co Ltd | Elastase activity inhibitor and cosmetic composition |
EP1441693A1 (en) | 2001-10-29 | 2004-08-04 | Showa Denko K.K. | Skin preparation comprising a tocopherol derivative for external application |
ES2465575T3 (en) * | 2002-09-09 | 2014-06-06 | Nestec S.A. | Orally administrable composition to improve hair and skin quality |
WO2004071519A1 (en) | 2003-01-14 | 2004-08-26 | Bruneau Francois | Photosynthetic micro-organisms enriched with biologically-active molecules, preparation method thereof and uses of same |
FR2867973A1 (en) | 2004-03-26 | 2005-09-30 | B Prince Sarl Lab | Capillary care composition, useful to e.g. treat alopecia, comprises Sabal, which is an extract of Serenoa serrulata in association with a vehicle |
EP3398606B1 (en) | 2006-01-19 | 2021-09-15 | Algenist Holdings, Inc, | Microalgae-derived compositions for improving the health and appearance of skin |
US20070166266A1 (en) | 2006-01-19 | 2007-07-19 | Solazyme, Inc. | Methods and compositions for improving the health and appearance of skin |
JP5132139B2 (en) | 2006-11-30 | 2013-01-30 | 株式会社ノエビア | External preparation for skin and food and drink |
WO2008114082A1 (en) * | 2007-03-21 | 2008-09-25 | Dorr Felt Tippens | Methods, processes and compositions comprising the protein calmodulin (cam) for treatment of damaged or ageing skin, and/or hair loss |
MX299318B (en) * | 2007-11-19 | 2012-05-18 | Stiefel Laboratories | Topical cosmetic skin lightening compositions and methods of use thereof. |
ES2628407T3 (en) * | 2008-04-01 | 2017-08-02 | Antipodean Pharmaceuticals, Inc. | Compositions and procedures for skin care |
US20110038882A1 (en) * | 2009-08-17 | 2011-02-17 | National Taiwan University | Methods for Treating Allergic Disease |
ITMI20130218A1 (en) * | 2013-02-18 | 2014-08-19 | Giuliani Spa | COMPOSITION FOR COSMETIC USE TO PRODUCE A HAIR PIGMENTATION EFFECT |
CN103356998A (en) * | 2013-06-14 | 2013-10-23 | 南京明生医药技术有限公司 | Composition for treating human white hair and/or leucoderma and application thereof |
CN104940049B (en) | 2014-03-28 | 2018-01-02 | 浙江大学 | Extracting method, extract and the application of yacon plant extracts |
-
2016
- 2016-11-03 US US15/342,922 patent/US10206861B2/en active Active
- 2016-11-03 EP EP16866845.7A patent/EP3377084A4/en active Pending
- 2016-11-03 JP JP2018526632A patent/JP7411327B2/en active Active
- 2016-11-03 AU AU2016357227A patent/AU2016357227A1/en not_active Abandoned
- 2016-11-03 WO PCT/US2016/060306 patent/WO2017087177A2/en active Application Filing
- 2016-11-03 EA EA201891183A patent/EA201891183A1/en unknown
- 2016-11-03 KR KR1020187017103A patent/KR20180081602A/en not_active Application Discontinuation
- 2016-11-03 US US15/342,947 patent/US10675233B2/en active Active
- 2016-11-03 CN CN201680076646.5A patent/CN108472322A/en active Pending
- 2016-11-03 CA CA3005842A patent/CA3005842A1/en active Pending
-
2019
- 2019-01-22 HK HK19101042.5A patent/HK1258675A1/en unknown
-
2020
- 2020-06-08 US US16/895,990 patent/US20200297608A1/en not_active Abandoned
-
2022
- 2022-07-05 AU AU2022204824A patent/AU2022204824A1/en not_active Abandoned
-
2024
- 2024-09-13 AU AU2024219724A patent/AU2024219724A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2024219724A1 (en) | 2024-10-10 |
WO2017087177A3 (en) | 2017-07-13 |
CN108472322A (en) | 2018-08-31 |
AU2022204824A1 (en) | 2022-07-28 |
US20170135949A1 (en) | 2017-05-18 |
EP3377084A4 (en) | 2019-08-07 |
US10675233B2 (en) | 2020-06-09 |
CA3005842A1 (en) | 2017-05-26 |
JP2018534337A (en) | 2018-11-22 |
WO2017087177A2 (en) | 2017-05-26 |
US20170135925A1 (en) | 2017-05-18 |
KR20180081602A (en) | 2018-07-16 |
JP7411327B2 (en) | 2024-01-11 |
EP3377084A2 (en) | 2018-09-26 |
EA201891183A1 (en) | 2018-12-28 |
US10206861B2 (en) | 2019-02-19 |
HK1258675A1 (en) | 2019-11-15 |
AU2016357227A1 (en) | 2018-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10675233B2 (en) | Compositions containing natural extracts and use thereof for skin and hair | |
US8709511B2 (en) | External preparation composition for skin comprising ginseng flower or ginseng seed extracts | |
EP3609469B1 (en) | Cosmetic preparation containing white truffle extract and cosmetic method thereof | |
CA2799223C (en) | Compositions and methods for stimulating magp-1 to improve the appearance of skin | |
US8231916B2 (en) | Use of a rice protein hydrolysate as pigmenting active principle | |
WO2021104214A1 (en) | Use of exosome derived from carcass in skin regulation product | |
CN109862878B (en) | Aqueous extract of peach blossom and method for preparing the same | |
JP4425163B2 (en) | Anti-aging cosmetics | |
KR102667277B1 (en) | Extract of Moringa peregrina seed cake, process for its preparation and use thereof in cosmetic or nutricosmetic compositions | |
KR20220122452A (en) | Method for manufacturing microalgae extract and cosmetic composition for wrinkle improvement using peptide complex obtained from microalgae extract | |
TW201420127A (en) | Extract of Phalaenopsis amabilis meristem, and the preparation process and uses thereof | |
EP3801778B1 (en) | Use of a bixa orellana extract | |
US11020340B2 (en) | Compositions containing natural products and use thereof for skin and hair | |
NL2029500B1 (en) | Cosmetic preparation using hedychium coronarium as an anti-aging skin care factor and preparation method thereof | |
BR122024004006A2 (en) | MORINGA PEREGRINA SEED PIE EXTRACT, COSMETIC AND NUTRICOSMETICAL COMPOSITIONS AND USE THEREOF | |
KR20220044488A (en) | New cosmetic use of pink needle flower extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SEIBERG CONSULTING, LLC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SEIBERG, MIRI;REEL/FRAME:052870/0365 Effective date: 20161019 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |